CA2356840A1 - Compositions and methods of using the same - Google Patents
Compositions and methods of using the same Download PDFInfo
- Publication number
- CA2356840A1 CA2356840A1 CA002356840A CA2356840A CA2356840A1 CA 2356840 A1 CA2356840 A1 CA 2356840A1 CA 002356840 A CA002356840 A CA 002356840A CA 2356840 A CA2356840 A CA 2356840A CA 2356840 A1 CA2356840 A1 CA 2356840A1
- Authority
- CA
- Canada
- Prior art keywords
- total weight
- composition
- skin
- barrier
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 332
- 238000000034 method Methods 0.000 title claims description 64
- 230000004888 barrier function Effects 0.000 claims abstract description 134
- 239000000463 material Substances 0.000 claims abstract description 126
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 115
- 238000012546 transfer Methods 0.000 claims abstract description 94
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000000758 substrate Substances 0.000 claims abstract description 45
- 239000013543 active substance Substances 0.000 claims abstract description 42
- 230000001681 protective effect Effects 0.000 claims abstract description 26
- -1 Aluminum Chlorhydrate Aluminum Chlorhydroxide Aluminum Chloride Hexahydrate Chemical compound 0.000 claims description 65
- 239000000787 lecithin Substances 0.000 claims description 55
- 235000010445 lecithin Nutrition 0.000 claims description 54
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 50
- 229940067606 lecithin Drugs 0.000 claims description 49
- 230000002209 hydrophobic effect Effects 0.000 claims description 29
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 22
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 22
- 229920001661 Chitosan Polymers 0.000 claims description 22
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 22
- 229920000642 polymer Polymers 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 11
- 239000011521 glass Substances 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 8
- 239000000356 contaminant Substances 0.000 claims description 8
- 229920003023 plastic Polymers 0.000 claims description 8
- 239000004033 plastic Substances 0.000 claims description 8
- 239000002023 wood Substances 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 6
- 239000011111 cardboard Substances 0.000 claims description 6
- 229960001810 meprednisone Drugs 0.000 claims description 6
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 239000011152 fibreglass Substances 0.000 claims description 5
- 239000010985 leather Substances 0.000 claims description 5
- 239000000516 sunscreening agent Substances 0.000 claims description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 4
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 claims description 4
- 238000010411 cooking Methods 0.000 claims description 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 229960002673 sulfacetamide Drugs 0.000 claims description 4
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 claims description 4
- 229960001727 tretinoin Drugs 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 230000001151 other effect Effects 0.000 claims description 3
- ITSHGFVZBGPCDF-UHFFFAOYSA-N (2-hydroxy-4-methoxyphenyl)-phenylmethanone octyl 2-methoxy-3-phenylprop-2-enoate Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1.CCCCCCCCOC(=O)C(OC)=CC1=CC=CC=C1 ITSHGFVZBGPCDF-UHFFFAOYSA-N 0.000 claims description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 claims description 2
- AJZJIYUOOJLBAU-ZYIUJVGZSA-N (2r,3s)-2,3-dihydroxybutanedioic acid;(2s)-n,n,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O.C1=CC=C2N(C[C@H](CN(C)C)C)C3=CC=CC=C3SC2=C1.C1=CC=C2N(C[C@H](CN(C)C)C)C3=CC=CC=C3SC2=C1 AJZJIYUOOJLBAU-ZYIUJVGZSA-N 0.000 claims description 2
- RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 claims description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N 1,4-Benzenediol Natural products OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 claims description 2
- WFNAKBGANONZEQ-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 WFNAKBGANONZEQ-UHFFFAOYSA-N 0.000 claims description 2
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 claims description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 claims description 2
- HZLHRDBTVSZCBS-UVJJDBRNSA-N 4-[(e)-(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline;hydrochloride Chemical compound Cl.C1=CC(=N)C(C)=C\C1=C(C=1C=C(C)C(N)=CC=1)/C1=CC=C(N)C=C1 HZLHRDBTVSZCBS-UVJJDBRNSA-N 0.000 claims description 2
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 claims description 2
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 2
- 108010001478 Bacitracin Proteins 0.000 claims description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 2
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 claims description 2
- 102000029816 Collagenase Human genes 0.000 claims description 2
- 108060005980 Collagenase Proteins 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 2
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 claims description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 2
- 108010088842 Fibrinolysin Proteins 0.000 claims description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 2
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims description 2
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims description 2
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 claims description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 2
- 102000001974 Hyaluronidases Human genes 0.000 claims description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 2
- UILOTUUZKGTYFQ-UHFFFAOYSA-N Mafenide acetate Chemical compound CC(O)=O.NCC1=CC=C(S(N)(=O)=O)C=C1 UILOTUUZKGTYFQ-UHFFFAOYSA-N 0.000 claims description 2
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 claims description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 2
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 claims description 2
- YUGZHQHSNYIFLG-UHFFFAOYSA-N N-phenylcarbamic acid [2-[anilino(oxo)methoxy]-3-(1-piperidinyl)propyl] ester Chemical compound C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 YUGZHQHSNYIFLG-UHFFFAOYSA-N 0.000 claims description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 2
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 claims description 2
- 108090000526 Papain Proteins 0.000 claims description 2
- 108010093965 Polymyxin B Proteins 0.000 claims description 2
- SYCBXBCPLUFJID-UHFFFAOYSA-N Pramoxine hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 SYCBXBCPLUFJID-UHFFFAOYSA-N 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 108010023197 Streptokinase Proteins 0.000 claims description 2
- 244000028419 Styrax benzoin Species 0.000 claims description 2
- 235000000126 Styrax benzoin Nutrition 0.000 claims description 2
- CRKGMGQUHDNAPB-UHFFFAOYSA-N Sulconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 CRKGMGQUHDNAPB-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 235000008411 Sumatra benzointree Nutrition 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 102000004142 Trypsin Human genes 0.000 claims description 2
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 claims description 2
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 claims description 2
- DPWMKSJSGYEXBN-UHFFFAOYSA-M [K+].[I-].OS(O)(=O)=O Chemical compound [K+].[I-].OS(O)(=O)=O DPWMKSJSGYEXBN-UHFFFAOYSA-M 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 2
- 229960003099 amcinonide Drugs 0.000 claims description 2
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 claims description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 2
- 229960003942 amphotericin b Drugs 0.000 claims description 2
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 229960003071 bacitracin Drugs 0.000 claims description 2
- 229930184125 bacitracin Natural products 0.000 claims description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 2
- 229960005274 benzocaine Drugs 0.000 claims description 2
- 229960002130 benzoin Drugs 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- 229960002747 betacarotene Drugs 0.000 claims description 2
- 229960004648 betamethasone acetate Drugs 0.000 claims description 2
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 claims description 2
- 229960001102 betamethasone dipropionate Drugs 0.000 claims description 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims description 2
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 claims description 2
- 229960005354 betamethasone sodium phosphate Drugs 0.000 claims description 2
- 229960004311 betamethasone valerate Drugs 0.000 claims description 2
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 2
- 229960004008 butamben picrate Drugs 0.000 claims description 2
- ATAGSVCDFKGYPE-UHFFFAOYSA-N butamben picrate Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1.CCCCOC(=O)C1=CC=C(N)C=C1.OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O ATAGSVCDFKGYPE-UHFFFAOYSA-N 0.000 claims description 2
- 229960005074 butoconazole Drugs 0.000 claims description 2
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 2
- 229960005091 chloramphenicol Drugs 0.000 claims description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 2
- 229960004831 chlorcyclizine Drugs 0.000 claims description 2
- 229960003260 chlorhexidine Drugs 0.000 claims description 2
- 229960002152 chlorhexidine acetate Drugs 0.000 claims description 2
- WDFKMLRRRCGAKS-UHFFFAOYSA-N chloroxine Chemical compound C1=CN=C2C(O)=C(Cl)C=C(Cl)C2=C1 WDFKMLRRRCGAKS-UHFFFAOYSA-N 0.000 claims description 2
- 229960004736 chloroxine Drugs 0.000 claims description 2
- 229960004375 ciclopirox olamine Drugs 0.000 claims description 2
- 229960001747 cinchocaine Drugs 0.000 claims description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 2
- 229960002227 clindamycin Drugs 0.000 claims description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 2
- 229960005228 clioquinol Drugs 0.000 claims description 2
- 229960004703 clobetasol propionate Drugs 0.000 claims description 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 2
- 229960001357 clocortolone pivalate Drugs 0.000 claims description 2
- SXYZQZLHAIHKKY-GSTUPEFVSA-N clocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O SXYZQZLHAIHKKY-GSTUPEFVSA-N 0.000 claims description 2
- 239000011280 coal tar Substances 0.000 claims description 2
- 229960002424 collagenase Drugs 0.000 claims description 2
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 claims description 2
- FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 claims description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- 229960003290 cortisone acetate Drugs 0.000 claims description 2
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 claims description 2
- 229960003338 crotamiton Drugs 0.000 claims description 2
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 claims description 2
- 229960001815 cyclopentolate Drugs 0.000 claims description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 2
- 229960000860 dapsone Drugs 0.000 claims description 2
- 229960003662 desonide Drugs 0.000 claims description 2
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims description 2
- 229960002593 desoximetasone Drugs 0.000 claims description 2
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims description 2
- 229940109357 desoxyribonuclease Drugs 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003657 dexamethasone acetate Drugs 0.000 claims description 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims description 2
- 229960005215 dichloroacetic acid Drugs 0.000 claims description 2
- 229960003887 dichlorophen Drugs 0.000 claims description 2
- 229960002124 diflorasone diacetate Drugs 0.000 claims description 2
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 claims description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002228 diperodon Drugs 0.000 claims description 2
- 229960002311 dithranol Drugs 0.000 claims description 2
- 229960003645 econazole nitrate Drugs 0.000 claims description 2
- 229960002179 ephedrine Drugs 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 229960005309 estradiol Drugs 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 claims description 2
- 229960002199 etretinate Drugs 0.000 claims description 2
- 229940001501 fibrinolysin Drugs 0.000 claims description 2
- 229960004511 fludroxycortide Drugs 0.000 claims description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 2
- 229960000785 fluocinonide Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960000289 fluticasone propionate Drugs 0.000 claims description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 2
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 claims description 2
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 229960002867 griseofulvin Drugs 0.000 claims description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 2
- 229960002146 guaifenesin Drugs 0.000 claims description 2
- 235000019382 gum benzoic Nutrition 0.000 claims description 2
- 229960002383 halcinonide Drugs 0.000 claims description 2
- 229960001906 haloprogin Drugs 0.000 claims description 2
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004068 hexachlorophene Drugs 0.000 claims description 2
- 229960002773 hyaluronidase Drugs 0.000 claims description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 2
- 229960000240 hydrocodone Drugs 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 claims description 2
- 229960001524 hydrocortisone butyrate Drugs 0.000 claims description 2
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 claims description 2
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 claims description 2
- 229960000631 hydrocortisone valerate Drugs 0.000 claims description 2
- 229960000930 hydroxyzine Drugs 0.000 claims description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 2
- 229960001560 hydroxyzine pamoate Drugs 0.000 claims description 2
- 229960005280 isotretinoin Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims description 2
- 229960002809 lindane Drugs 0.000 claims description 2
- 229960002721 mafenide acetate Drugs 0.000 claims description 2
- 229960004737 meclocycline sulfosalicylate Drugs 0.000 claims description 2
- 229960004469 methoxsalen Drugs 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960005040 miconazole nitrate Drugs 0.000 claims description 2
- 229960003632 minoxidil Drugs 0.000 claims description 2
- 229960002744 mometasone furoate Drugs 0.000 claims description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 2
- 229960000990 monobenzone Drugs 0.000 claims description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 229940053050 neomycin sulfate Drugs 0.000 claims description 2
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims description 2
- 229960001907 nitrofurazone Drugs 0.000 claims description 2
- 229960000988 nystatin Drugs 0.000 claims description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 2
- 229960001257 oxyquinoline sulfate Drugs 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 229960000490 permethrin Drugs 0.000 claims description 2
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 claims description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003562 phentermine Drugs 0.000 claims description 2
- 229960003548 polymyxin b sulfate Drugs 0.000 claims description 2
- 229960002794 prednicarbate Drugs 0.000 claims description 2
- FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 claims description 2
- 229960002943 prednisolone sodium phosphate Drugs 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims description 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 2
- 229960003908 pseudoephedrine Drugs 0.000 claims description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 2
- 229930002330 retinoic acid Natural products 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229960003600 silver sulfadiazine Drugs 0.000 claims description 2
- 229940074404 sodium succinate Drugs 0.000 claims description 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 2
- JLDCNMJPBBKAHH-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide Chemical compound [Na+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 JLDCNMJPBBKAHH-UHFFFAOYSA-N 0.000 claims description 2
- 229960005202 streptokinase Drugs 0.000 claims description 2
- 229960002607 sulconazole Drugs 0.000 claims description 2
- 229960004718 sulconazole nitrate Drugs 0.000 claims description 2
- 229960004730 sulfabenzamide Drugs 0.000 claims description 2
- PBCZLFBEBARBBI-UHFFFAOYSA-N sulfabenzamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC(=O)C1=CC=CC=C1 PBCZLFBEBARBBI-UHFFFAOYSA-N 0.000 claims description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001544 sulfathiazole Drugs 0.000 claims description 2
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 108010022069 sultilains Proteins 0.000 claims description 2
- 229950010549 sutilains Drugs 0.000 claims description 2
- 229960000580 terconazole Drugs 0.000 claims description 2
- YUSMZDVTEOAHDL-NTMALXAHSA-N tert-butyl (3z)-3-(dimethylaminomethylidene)-4-oxopiperidine-1-carboxylate Chemical compound CN(C)\C=C1\CN(C(=O)OC(C)(C)C)CCC1=O YUSMZDVTEOAHDL-NTMALXAHSA-N 0.000 claims description 2
- 229960002372 tetracaine Drugs 0.000 claims description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 229960005294 triamcinolone Drugs 0.000 claims description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- 229960004320 triamcinolone diacetate Drugs 0.000 claims description 2
- 229940076784 trimeprazine tartrate Drugs 0.000 claims description 2
- FMHHVULEAZTJMA-UHFFFAOYSA-N trioxsalen Chemical compound CC1=CC(=O)OC2=C1C=C1C=C(C)OC1=C2C FMHHVULEAZTJMA-UHFFFAOYSA-N 0.000 claims description 2
- 229960000850 trioxysalen Drugs 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- 229950008396 ulobetasol propionate Drugs 0.000 claims description 2
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
- 229920000049 Carbon (fiber) Polymers 0.000 claims 2
- 239000004917 carbon fiber Substances 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 239000004744 fabric Substances 0.000 claims 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 2
- 239000000123 paper Substances 0.000 claims 2
- 239000011347 resin Substances 0.000 claims 2
- 229920005989 resin Polymers 0.000 claims 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 1
- YYYARFHFWYKNLF-UHFFFAOYSA-N 4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=C12 YYYARFHFWYKNLF-UHFFFAOYSA-N 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 229960004229 alclometasone dipropionate Drugs 0.000 claims 1
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 claims 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims 1
- 229960004022 clotrimazole Drugs 0.000 claims 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims 1
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 claims 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims 1
- 229960004313 naftifine Drugs 0.000 claims 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 claims 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 claims 1
- 239000000853 adhesive Substances 0.000 abstract description 3
- 230000001070 adhesive effect Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 190
- 238000009472 formulation Methods 0.000 description 43
- 239000001993 wax Substances 0.000 description 37
- 238000012360 testing method Methods 0.000 description 35
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 29
- 229960004867 hexetidine Drugs 0.000 description 28
- 150000001875 compounds Chemical class 0.000 description 22
- 125000000129 anionic group Chemical group 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 18
- 230000008901 benefit Effects 0.000 description 16
- 239000004205 dimethyl polysiloxane Substances 0.000 description 15
- 239000004615 ingredient Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- 125000002091 cationic group Chemical group 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 239000003085 diluting agent Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 description 10
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 9
- 208000003251 Pruritus Diseases 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 230000035699 permeability Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000011253 protective coating Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 229920001296 polysiloxane Polymers 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000001815 facial effect Effects 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229920002873 Polyethylenimine Polymers 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 description 6
- 239000004200 microcrystalline wax Substances 0.000 description 6
- 235000019808 microcrystalline wax Nutrition 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 239000003760 tallow Substances 0.000 description 6
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 6
- 201000004647 tinea pedis Diseases 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 239000003945 anionic surfactant Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000000919 ceramic Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- XXUJMEYKYHETBZ-UHFFFAOYSA-N ethyl 4-nitrophenyl ethylphosphonate Chemical compound CCOP(=O)(CC)OC1=CC=C([N+]([O-])=O)C=C1 XXUJMEYKYHETBZ-UHFFFAOYSA-N 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- 150000003839 salts Chemical group 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 201000010618 Tinea cruris Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000002924 anti-infective effect Effects 0.000 description 4
- 239000003093 cationic surfactant Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000005660 hydrophilic surface Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 4
- 239000011087 paperboard Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 229920000768 polyamine Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 3
- 239000005662 Paraffin oil Substances 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 229920000867 polyelectrolyte Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- MLQBTMWHIOYKKC-KTKRTIGZSA-N (z)-octadec-9-enoyl chloride Chemical class CCCCCCCC\C=C/CCCCCCCC(Cl)=O MLQBTMWHIOYKKC-KTKRTIGZSA-N 0.000 description 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical class CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 101710140999 Metallocarboxypeptidase inhibitor Proteins 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 229920001774 Perfluoroether Polymers 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 241000159241 Toxicodendron Species 0.000 description 2
- 241000159243 Toxicodendron radicans Species 0.000 description 2
- 241000871311 Toxicodendron vernix Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000005210 alkyl ammonium group Chemical group 0.000 description 2
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000000058 anti acne agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003373 anti-fouling effect Effects 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 229940124340 antiacne agent Drugs 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- NAPSCFZYZVSQHF-UHFFFAOYSA-N dimantine Chemical compound CCCCCCCCCCCCCCCCCCN(C)C NAPSCFZYZVSQHF-UHFFFAOYSA-N 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000002052 molecular layer Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- YTTCNBZCKGAEJC-UHFFFAOYSA-N n'-ethylpropane-1,3-diamine Chemical compound CCNCCCN.CCNCCCN YTTCNBZCKGAEJC-UHFFFAOYSA-N 0.000 description 2
- LYYLWJOKAQADDU-UHFFFAOYSA-N n,n-dihexadecylhexadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCC)CCCCCCCCCCCCCCCC LYYLWJOKAQADDU-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920002620 polyvinyl fluoride Polymers 0.000 description 2
- 229920002717 polyvinylpyridine Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- NXLOLUFNDSBYTP-UHFFFAOYSA-N retene Chemical compound C1=CC=C2C3=CC=C(C(C)C)C=C3C=CC2=C1C NXLOLUFNDSBYTP-UHFFFAOYSA-N 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- GKQHIYSTBXDYNQ-UHFFFAOYSA-M 1-dodecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+]1=CC=CC=C1 GKQHIYSTBXDYNQ-UHFFFAOYSA-M 0.000 description 1
- WDRZVZVXHZNSFG-UHFFFAOYSA-N 1-ethenylpyridin-1-ium Chemical compound C=C[N+]1=CC=CC=C1 WDRZVZVXHZNSFG-UHFFFAOYSA-N 0.000 description 1
- HJNAJKBRYDFICV-UHFFFAOYSA-M 1-tetradecylpyridin-1-ium;bromide Chemical compound [Br-].CCCCCCCCCCCCCC[N+]1=CC=CC=C1 HJNAJKBRYDFICV-UHFFFAOYSA-M 0.000 description 1
- YOFPVMWVLDSWKR-UHFFFAOYSA-N 11-methyl-n-(11-methyldodecyl)dodecan-1-amine Chemical compound CC(C)CCCCCCCCCCNCCCCCCCCCCC(C)C YOFPVMWVLDSWKR-UHFFFAOYSA-N 0.000 description 1
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 1
- ZITBHNVGLSVXEF-UHFFFAOYSA-N 2-[2-(16-methylheptadecoxy)ethoxy]ethanol Chemical compound CC(C)CCCCCCCCCCCCCCCOCCOCCO ZITBHNVGLSVXEF-UHFFFAOYSA-N 0.000 description 1
- NDLNTMNRNCENRZ-UHFFFAOYSA-N 2-[2-hydroxyethyl(octadecyl)amino]ethanol Chemical compound CCCCCCCCCCCCCCCCCCN(CCO)CCO NDLNTMNRNCENRZ-UHFFFAOYSA-N 0.000 description 1
- FDENMUFFUJNUTA-UHFFFAOYSA-M 2-hydroxydodecyl-(2-hydroxyethyl)-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCC(O)C[N+](C)(C)CCO FDENMUFFUJNUTA-UHFFFAOYSA-M 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 244000166675 Cymbopogon nardus Species 0.000 description 1
- 235000018791 Cymbopogon nardus Nutrition 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 description 1
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010061304 Nail infection Diseases 0.000 description 1
- QSDSSSQWVNLFIG-UHFFFAOYSA-N Neosporin Natural products CC(O)CC1=C(OC)C(=O)C2=CC(O)=C3OCOC4=C(O)C=C5C6=C4C3=C2C1=C6C(CC(C)O)=C(OC)C5=O QSDSSSQWVNLFIG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282372 Panthera onca Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- YJVBLROMQZEFPA-UHFFFAOYSA-L acid red 26 Chemical compound [Na+].[Na+].CC1=CC(C)=CC=C1N=NC1=C(O)C(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=CC=C12 YJVBLROMQZEFPA-UHFFFAOYSA-L 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229960000552 alclometasone Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000002714 alpha-linolenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])[H] 0.000 description 1
- UPOYFZYFGWBUKL-UHFFFAOYSA-N amiphenazole Chemical class S1C(N)=NC(N)=C1C1=CC=CC=C1 UPOYFZYFGWBUKL-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000002519 antifouling agent Substances 0.000 description 1
- 125000002886 arachidonoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical group [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960004830 cetylpyridinium Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- RYJIRNNXCHOUTQ-OJJGEMKLSA-L cortisol sodium phosphate Chemical compound [Na+].[Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 RYJIRNNXCHOUTQ-OJJGEMKLSA-L 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 229960004670 didecyldimethylammonium chloride Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000006182 dimethyl benzyl group Chemical group 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108010046161 drug combination polymyxin B neomycin sulfate bacitracin zinc Proteins 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000011440 grout Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229910001512 metal fluoride Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 108091005592 methylated proteins Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000000050 mohair Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- PZFYOFFTIYJCEW-UHFFFAOYSA-N n-tridecyltridecan-1-amine Chemical compound CCCCCCCCCCCCCNCCCCCCCCCCCCC PZFYOFFTIYJCEW-UHFFFAOYSA-N 0.000 description 1
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
- 229940049337 neosporin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000001282 organosilanes Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 125000001236 palmitoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229940096017 silver fluoride Drugs 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- REYHXKZHIMGNSE-UHFFFAOYSA-M silver monofluoride Chemical compound [F-].[Ag+] REYHXKZHIMGNSE-UHFFFAOYSA-M 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- MQRFYYBWKRACSJ-WKSAPEMMSA-L sodium;[2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate Chemical compound [Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O MQRFYYBWKRACSJ-WKSAPEMMSA-L 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000013460 sweaty Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000005494 tarnishing Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000004764 thiosulfuric acid derivatives Chemical class 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/38—Percompounds, e.g. peracids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Adhesives Or Adhesive Processes (AREA)
Abstract
The present invention discloses compositions containing a one or more transfer agents and one or more barrier materials which form, upon application to a substrate, even a wet substrate or substrate immersed under water, adhesive, protective barriers. The compositions may be modified to provide an appropriate viscosity and other characteristics and may serve as a carrier for active agents.
Description
TITLE OF THE INVENTION
COMPOSITIONS AND METHODS OF USING THE SAME
This application claims priority to L1.S. Provisional Application Serial Nos.
60/113,950, filed December 24, 1998, and 60/117,283, filed January 26, 1999.
BA~~GROUND OF THE INVENTION
Field of the Invention:
The present invention relates to compositions and methods of using the same.
In particular, the present invention relates to novel protective compositions and methods of treating certain surfaces. In a preferred embodiment, the present invention relates to skin care and specifically to methods of treating the skin, even wet skin or skin which is immersed in water, with compositions, which provide the skin with a protective barrier. The present invention also relates to compositions which provide the skin, even wet skin or skin which is immersed in water, with a protective barrier.
The present invention also relates to compositions which can clean and remove contamination from the skin while applying a protective barrier. Throughout this invention, the term "skin" is meant to include not only the exterior integument or dermis/epidermis/stratum corneum of man but also the internal and external surfaces of organs and vessels including wounds, linings, membranous surfaces and glomeruli of man and other animals, and other surfaces such as glass, metal, paint, plastic, and all others which, like skin, can be electrostatically negatively charged.
Discussion of the Backsround:
Numerous types of skin care compositions are known. For example, skin care compositions are often classified as being either medicated or non-medicated.
Other types of skin care compositions include, e.g., sun blockers, moisturizers, etc.
However, two general drawbacks of many skin care compositions are that they are difficult or impossible to apply to wet (or sweaty) skin and they are easily removed from the skin. Thus, one goal of the present invention is to provide skin care compositions which provide a long-lasting, protective barrier on the skin.
Another goal of this invention is to provide skin care compositions which can effectively and aesthetically be applied to skin which is wet or even immersed under water or aqueous solutions. Yet another goal of this invention is to provide skin care compositions which can effectively and aesthetically be applied to skin to clean and remove contaminants from skin which is wet or even immersed under water or aqueous solutions.
~j~MMARY OF THE INVENTION
Accordingly, it is one object of the present invention to provide novel skin care compositions.
It is another object of the present invention to provide novel skin care compositions which provide a long-lasting protective barrier on the skin.
It is another object of the present invention to provide a method for treating the skin which confers improved protection to the skin.
COMPOSITIONS AND METHODS OF USING THE SAME
This application claims priority to L1.S. Provisional Application Serial Nos.
60/113,950, filed December 24, 1998, and 60/117,283, filed January 26, 1999.
BA~~GROUND OF THE INVENTION
Field of the Invention:
The present invention relates to compositions and methods of using the same.
In particular, the present invention relates to novel protective compositions and methods of treating certain surfaces. In a preferred embodiment, the present invention relates to skin care and specifically to methods of treating the skin, even wet skin or skin which is immersed in water, with compositions, which provide the skin with a protective barrier. The present invention also relates to compositions which provide the skin, even wet skin or skin which is immersed in water, with a protective barrier.
The present invention also relates to compositions which can clean and remove contamination from the skin while applying a protective barrier. Throughout this invention, the term "skin" is meant to include not only the exterior integument or dermis/epidermis/stratum corneum of man but also the internal and external surfaces of organs and vessels including wounds, linings, membranous surfaces and glomeruli of man and other animals, and other surfaces such as glass, metal, paint, plastic, and all others which, like skin, can be electrostatically negatively charged.
Discussion of the Backsround:
Numerous types of skin care compositions are known. For example, skin care compositions are often classified as being either medicated or non-medicated.
Other types of skin care compositions include, e.g., sun blockers, moisturizers, etc.
However, two general drawbacks of many skin care compositions are that they are difficult or impossible to apply to wet (or sweaty) skin and they are easily removed from the skin. Thus, one goal of the present invention is to provide skin care compositions which provide a long-lasting, protective barrier on the skin.
Another goal of this invention is to provide skin care compositions which can effectively and aesthetically be applied to skin which is wet or even immersed under water or aqueous solutions. Yet another goal of this invention is to provide skin care compositions which can effectively and aesthetically be applied to skin to clean and remove contaminants from skin which is wet or even immersed under water or aqueous solutions.
~j~MMARY OF THE INVENTION
Accordingly, it is one object of the present invention to provide novel skin care compositions.
It is another object of the present invention to provide novel skin care compositions which provide a long-lasting protective barrier on the skin.
It is another object of the present invention to provide a method for treating the skin which confers improved protection to the skin.
It is another object of the present invention to provide novel skin care compositions which can be effectively and aesthetically applied to skin which is wet or even immersed under water or aqueous solutions.
It is another object of the present invention to provide novel skin care compositions which can effectively and aesthetically be applied to skin to clean and remove contaminants from skin which is wet or even immersed under water or aqueous solutions.
These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that application of a composition which comprises:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of one or more barrier materials, to the skin results in the formation of a protective barrier on the skin.
The inventors have also discovered that compositions which comprise:
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'~ 0.25 to 99.99 wt.%, based on the total weight of (b'~ and (b"'), of ane or more transfer agents; and (b"') 0.01 to 99.75 wt.%, based on the total weight of (b'~ and (b"'), of one or more skin care agents.
provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition, are useful for applying the skin care agent to the skin.
The inventors have also discovered that compositions comprising:
( 1 ) 25 to 80 wt.%, based on the total weight of ( 1 ), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water, are useful for applying the skin care agent to the skin.
The inventors have also discovered that compositions comprising:
(i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier I S material; and (iii) 1 to 50 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan, are useful as skin care formulations.
Thus, the present invention provides new compositions which form long-lasting, protective barriers an the skin and can be effectively and aesthetically applied to wet or dry skin, skin which is covered with sweat or other secretions, skin which is soiled or contaminated or skin which is immersed under water or aqueous solutions.
The methods of this invention result in the electrostatic bonding of waxy materials to the skin.
It is another object of the present invention to provide novel skin care compositions which can effectively and aesthetically be applied to skin to clean and remove contaminants from skin which is wet or even immersed under water or aqueous solutions.
These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that application of a composition which comprises:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of one or more barrier materials, to the skin results in the formation of a protective barrier on the skin.
The inventors have also discovered that compositions which comprise:
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'~ 0.25 to 99.99 wt.%, based on the total weight of (b'~ and (b"'), of ane or more transfer agents; and (b"') 0.01 to 99.75 wt.%, based on the total weight of (b'~ and (b"'), of one or more skin care agents.
provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition, are useful for applying the skin care agent to the skin.
The inventors have also discovered that compositions comprising:
( 1 ) 25 to 80 wt.%, based on the total weight of ( 1 ), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water, are useful for applying the skin care agent to the skin.
The inventors have also discovered that compositions comprising:
(i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier I S material; and (iii) 1 to 50 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan, are useful as skin care formulations.
Thus, the present invention provides new compositions which form long-lasting, protective barriers an the skin and can be effectively and aesthetically applied to wet or dry skin, skin which is covered with sweat or other secretions, skin which is soiled or contaminated or skin which is immersed under water or aqueous solutions.
The methods of this invention result in the electrostatic bonding of waxy materials to the skin.
The compositions of the present invention may be applied to the skin either by hand or by using any of a variety of skin application appliances, such as an atomizer, spray can, brush, wipe, cotton puff, roll-on device, or other system or device particularly applicable to the specific surface being treated.
The materials used for covering the applicator-ends of the appliance may include, for example: a) natural or synthetic yarn, filaments, or other fibrous material either as such or assembled as a textile, or to any braided, stranded, woven, non-woven, knitted, matted, felted, etc. material, in which the materials of the composition of the present invention (hereinafter MCPI) are held among or between the fibers or the strands of the materials; b) foam-like or otherwise porous materials in which the MCPI are held within pores or apertures; or c) non-porous, non-fibrous materials such as some types of wood, plastic, metal, etc.
Thus, in one embodiment of the present invention, a single monolayer is composed of a low molecular weight transfer agent in which positively charged groups react with the negatively charged surfaces of the skin and the water repelling part of the hydrophobic chain forms a highly hydrophobic interface. Examples of such transfer agents are cetyltrimethylammonium bromide (CTAB), hexadecyltrimethylammonium bromide (HDTAB), 5-amino-1,3-bis(2-ethylhexyl)-5-methylhexahydro-5-methylpyrimidine (hexetidine) and various amines and quaternary amines, of which a good example is Hyamine-1622 quaternary amine.
The compositions of the present invention are generally liquid, semi-solid or solid state materials which may be applied to skin surfaces by hand, by pouring, by injection, or by flowing. For the compositions of the present invention to be applied -S-through the use of an atomizer, spray can, brush, wipe, cotton puff; roll-on device, or any other applicator or method of application by which liquid, semi-solid, or solid materials may be brought into contact with the skin, it may be necessary to modify the viscosity of the composition with suitable volatile solvents known in the art or to form emulsions by known means to provide formulations of appropriate viscosities.
The compositions of the present invention, as applied to the skin, provide a mufti-component protective coating (hereafter called the "Protective Coating:
or "PC"), as follows:
(1) The transfer agent component has dual functionality, being composed of materials having some molecular segments or parts of a polymeric chain which are positively charged and other such segments which exhibit hydrophobic characteristics.
(2) The barrier component is a hydrophobic, inert material (hereafter called the "barrier" material), such as a wax or polydimethylsiloxane which mixes with and adheres to the relatively uncharged, hydrophobic molecular segments or parts of the transfer agent molecule. The thickness of the barrier stratum is typically between about 1 and about 10 microns but can be thinner or thicker depending on the requirements of the particular application.
(3) Compositions of the present invention may optionally include one or more active agents which are intended to provide specific medical, cosmetic, or other effects according to the known art relating to such ingredients.
-(i-nFTAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Thus, in a first embodiment, the present invention provides novel compositions which comprise:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of one or more barrier materials.
Preferably, the present composition contains:
(a) 1 to 12 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 88 to 99 wt.%, based on the total weight of (a) and (b), of one or more barrier materials.
In a second embodiment, the present invention provides novel compositions which comprise:
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'~ 0.25 to 99.99 wt.%, based on the total weight of (b'~ and (b"'), of one or more transfer agents; and (b"') 0.01 to 99.75 wt.%, based on the total weight of (b'~ and (b"'), of one or more skin care agents, _7_ provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
Preferably, in this fifth embodiment, the present composition contains:
(a') 75 to 99 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 1 to 25 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'~ 1 to 99.9 wt.%, based on the total weight of (b'~ and (b"'), of one or more transfer agents; and (b"') 0.1 to 99 wt.%, based on the total weight of (b'~ and (b"'), of one or more skin care active agents, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
In a third embodiment, the present invention provides a method for forming a protective barrier on skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of transfer agent;
and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of a barner material.
Preferably, in this third embodiment, the present composition contains:
(a) 1 to 12 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and _g_ (b) 88 to 99 wt.%, based on the total weight of (a) and (b), of one or more barrier materials.
In a fourth embodiment, the present invention provides a method for cleaning and removing contamination from the skin while forming a protective barrier on skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of transfer agent; and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of a barrier material.
Preferably, in this fourth embodiment, the present composition contains:
(a) 1 to 12 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 88 to 99 wt.%, based on the total weight of (a) and (b), one or more barrier materials.
In a fifth embodiment, the present invention provides a method for applying a skin care agent to skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of ane or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'~ 0.25 to 99.99 wt.%, based on the total weight of (b'~ and (b"'), of one or more transfer agents; and (b"'} 0.01 to 99.75 wt.%, based on the total weight of (b'~ and (b"'), of at least one skin care agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
Preferably, in this fifth embodiment, the present composition contains:
(a') 75 to 99 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 1 to 25 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'~ 1 to 99.9 wt.%, based on the total weight of (b'~ and (b"'), of one or more transfer agents; and (b"') 0.1 to 99 wt.%, based on the total weight of (b'~ and (b"'), of one or more skin care active agents, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
In a sixth embodiment, the present invention provides a method for applying a skin care agent to the skin, which comprises applying to the skin a composition, said composition comprising:
(A) 5 to 90 wt.%, based on the total weight of (A) and (B), of one or more compositions described in the first or second embodiments; and (B) 10 to 95 wt.%, based on the total weight of (A) and (B), of one or more volatile diluents compatible with the other ingredients of the composition.
In a seventh embodiment, the present invention provides novel compositions which comprise:
(1) 25 to 80 wt.%, based on the total weight of {1), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water.
Preferably, in this seventh embodiment, the present composition contains:
(1) 30 to 60 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 10 to 40 wt.%, based on the total weight of (1), (2), and (3), of lecithin; and (3) 30 to 40 wt.%, based on the total weight of {1), (2), and (3), of water.
In an eighth embodiment, the present invention provides a method for applying a skin care agent to skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(1) 25 to 80 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water.
Preferably, in this eighth embodiment, the present composition contains:
(1) 30 to 60 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 10 to 40 wt.%, based on the total weight of (1), {2), and (3), of lecithin; and (3) 30 to 40 wt.%, based on the total weight of ( I ), (2), and (3), of water.
In an ninth embodiment, the present invention provides novel compositions which comprise:
{i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 1 to 50 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
Preferably, in this ninth embodiment, the present composition contains:
(i) S to 25 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 15 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 10 to 40 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
In a tenth embodiment, the present invention provides a method for applying a skin care agent to skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 1 to 50 wt.%, based on the total weight of (i), {ii), and (iii), of chitosan.
Preferably, in this tenth embodiment, the present composition comprises:
(i) 5 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
_ I 2-(ii) 15 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 10 to 40 wt.%, based on the total weight of (i), (ii), and {iii), of chitosan.
THE TRANSFER AGENT FUNCTION
To adhere a hydrophobic barrier material to the skin, especially to wet skin or skin immersed in water, a bi-functional transfer agent material is employed.
This material has some active groups which are electrostatically positively charged and some groups which are compatible with the hydrophobic materials of the barrier.
Useful transfer agent materials include various cetyl amine compounds, various diamines (including for example, Duomeens and Ethoduomeens), nitroparaffin-derived hetexocyclic amines, quaternary ammonium compounds, and the like. Also useful are compounds of certain cationic polyelectrolytes, including, for example, polyethyleneimine (PEI) derivatized with varying concentrations of fatty acids such as, for example, stearic acid, palmitic acid, oleic acid, etc.
Suitable transfer agents are disclosed in U.S. Patent Nos. 5,665,333, 5,888,480, 5,980,868, and 5,961,958 all of which are incorporated herein by reference in their entirety.
Transfer gent Materials:
Cationic transfer agent materials useful in the present invention are believed to attach to the skin via an electrostatic interaction between the cationic portion of the material and the negatively charged portion of the skin and thus predispose or condition the surface of the skin so that a waxy, hydrophobic material will then adhere to the surface. Transfer agent materials that are capable of strong electrostatic bonding to the negatively charged and hydrophilic surfaces of skin include various straight-chain alkylammonium compounds, cyclic alkylammonium compounds, petroleum derived cationics, lecithins, and the like.
a) Straight-chain alkylammonium compounds R' R' R' R-N-R" R-N+-H X- R-N~-R" X-R" R"' R represents a long (Cg_zo) alkyl chain which may be substituted with one or more hydroxy groups, R', R ", and R"' each independently may be either a long (CH_zo) alkyl chain which may be substituted with one or more hydroxy groups or a smaller (C,_4) alkyl groups which may be substituted with one or more hydroxy groups or aryl (C6_,o) groups or hydrogen, and X- represents an anion such as chloride or fluoride.
These schematic formulas are given for the purpose of defining the classes of compounds and represent the simplest concepts of cationic transfer agents whereby one or more hydrophobic alkyl groups are linked to a cationic nitrogen atom. In many instances the linkage is more complex as, for example, in RCONHCHZCHZCH,N(CH_3),. In addition, cationic transfer agents may contain more than one cationic nitrogen atom such as the following class of compounds RNHCHZCHZCHZNHZ and derivatives thereof.
Representative examples of compounds according to the above formulas are:
cetyl trimethylammonium bromide (CTAB), hexadecyltrimethylammonium bromide (HDTAB), stearyl dimethylbenzylammonium chloride, lauryl dimethylbenzylammonium chloride, cetyl dimethylethylammonium halide, cetyl dimethylbenzylammonium halide, cetyl trimethylammonium halide (bromide, chloride, fluoride), dodecyl ethyldimethylammonium halide, lauryl trimethylammonium halide, coconut aikyltrimethylammonium halide, N,N-C8_ZO-dialkyldimethylammonium halide, and specifically compounds such as bis(hydrogenated tallow alkyl) dimethylammonium chloride which is known to adsorb onto the surface with hydrophobic groups oriented away from it, 2-hydroxydodecyl-2-hydroxyethyl dimethyl ammonium chloride and N-octadecyl-N,N',N'-tris-(2-hydroxyethyl)-1,3-diaminopropane dihydrofluoride.
b) Cyclic Alkylammonium Compounds A further preferred group of compounds of the present invention which have been found to be applicable includes a class of surface-active quaternary ammonium compounds in which the nitrogen atom carrying the cationic charge is part of a heterocyclic ring. Suitable compounds, for example, are as follows:
laurylpyridinium chloride or bromide, tetradecylpyridinium bromide, cetylpyridinium halide (chloride, bromide or fluoride).
5-amino-1,3-bis(2-ethylhexyl)-5-methylhexahydro-5-methylpyrimidine (hexetidine) c) Petroleum Derived Cationics Typical basic amines are derived from petroleum-based raw materials such as olefins, paraffins, and aromatic hydrocarbons and include compounds with at least one aliphatic carbon chain containing six or more carbon atoms attached to the nitrogen.
Thus, amine salts, diamines, amidoamines, alkoxylated amines, and their respective quaternary salts are applicable.
Preferred compounds of this type include tallow or coco alkyl substituted 1,3-propylene diamines sold by Witco under the trade names of "Adogen" and "Emcol"
and similar diamines sold by Akzo under the trade name "Duomeen" and their polyethenoxy derivatives under the trade names of "Ethomeen" and "Ethoduomeens".
d) Polymeric Amines Suitable polymeric amines comprise a class of polymers containing ionic groups along the backbone chain and exhibit properties of both electrolytes and polymers. These materials contain nitrogen, of primary, secondary, tertiary or quaternary functionality in their backbone and may have weight average molecular weights as low as about 100 or higher than about 100,000. Representative of these polymeric cationic transfer agents are the following:
polydimeryl polyamine (General Mills Chemical Co.), polyamide (trade name "Versamide"), polyacrylamides, polydiallyldimethylammonium chloride ("Cat-Floc"), polyhexamethylene biguanide compounds as sold under the trade name "Vantocil", and also other biguanides, for example those disclosed in LJ.S. Patent Nos. 2,684,924, 2,990,425, 3,183,230, S 3,468,898, 4,022,834, 4,053,636 and 4,198,425, 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide ("Polybrene" from Aldrich), polyvinylpyrrolidone and their derivatives, polypeptides, poly(allylamine) hydrochloride, polyoxyethylenated amines, and specifically, polyethyleneimine ("Polymin" from BASF), and a class of related and surface active cationic polymers prepared by converting a fraction of the amino groups to their acyl derivatives. The polyethyleneimine is first condensed with less than the stoichiometric quantity of acid halides thus alkylating some of the amino groups and the remaining amino groups are then condensed with hydrogen halides such as hydrogen chloride or, preferentially, hydrogen fluoride. The surface activity of these compounds vary with the number of amino groups which are acylated, and with the chain length of the acylating group RCO-. The condensation reaction is typically performed with stearic or oleic acid chlorides in the presence of a solvent containing metal fluoride, preferentially silver fluoride, in such a manner that silver chloride formed in the reaction precipitates from the solvent, as described in _17_ Example XV of U.S. Patent No. 5,665,333, which is incorporated herein by reference in its entirety.
Also suitable, for the purpose of this invention, are cationic derivatives of polysaccharides such as dextran, starch or cellulose, for example, diethylaminoethyl cellulose ("DEAE-cellulose"). Examples of applicable copolymers based on acrylamide and a cationic monomer are available commercially under the trade name RETEN from Hercules Inc., or under the name FLOC AID from National Adhesives.
Particular examples of such polymers are FLOC AID 305 and RETEN 220. Similarly useful are acrylamide-based polyelectrolytes as sold by Allied Colloids under the trade name PERCOL. Further examples of suitable materials are the cationic guar derivatives such as those sold under the trade name JAGUAR by Celanese-Hall.
A further preferred group of compounds which comprises a class of water-insoluble polymers, having nitrogen atoms in their molecules, are quaternary polymers of quaternary ammonium type, betaine type, pyridylpyridinium type or vinylpyridinium type. Examples are as follows;
poly(vinyl-benzylmethyllaurylammonium chloride), poly(vinyl-benzylstearylbetaine), poly(vinyl-benzyllaurylpyridylpyridinium chloride), poly(vinyl-benzylcetylammonylhexyl ether) and quaternized polyoxyethyleneated long chain amines, with the general formula RN(CH3)[(CZHqO)xH]2{+) A(-), where A{-) is generally chloride or fluoride, x is a number from 1 to 20, and R is CR_2~-alkyl.
These cationic materials, by reacting with the surface of the skin, produce strongly hydrophobic films onto which hydrophobic barrier materials are easily transferred by brushing, rubbing, smearing, or burnishing.
It is important that the reason for this transferability be understood. The surface of human skin is normally hydrophilic and negatively charged. The transfer and adhesion of the barrier materials onto such surfaces is difficult or practically impossible unless the surface is modified by a material that is hydrophobic and therefore compatible with the barrier materials.
In a preferred embodiment, the transfer agent, a cationic surfactant, is a polymer which contains a nitrogen atom in a repeating unit and in which a portion of the nitrogen atoms are quaternized by formation of a salt with a C8_ZO fatty acid, preferably a C,2_zo fatty acid. Examples of such polymeric cationic surfactants include polyacrylamides, polyvinylpyridines, or polyamines, e.g., poly(ethyleneimine), in which from 5 to 95 mole%, preferably 40 to 60 mole%, of the nitrogen atoms have been quaternized by formation of a salt with a fatty acid. Typically such polymers will have a weight average molecular weight of 600 to 60,000, preferably 600 to 1,800.
In a another embodiment, the transfer agent is a polymer which contains a nitrogen atom in a repeating unit and in which a first portion of the nitrogen atoms are quaternized with a C8_Z° fatty acid, preferably a C,,_ZO fatty acid, and a second portion of the nitrogen atoms are quaternized by forming a salt with various acids such as hydrofluoric acid, etc. Examples of such polymeric cationic surfactants include polyacrylamides, polyvinylpyridines or polyamines, e.g., poly(ethyleneimine), in which from 5 to 95 mole%, preferably from 40 to 60 mole %, of the nitrogen atoms are converted to their acid derivatives by reaction with stearic or oleic acid chlorides, and from S to 95 mole%, preferably from 40 to 60 mole%, of the nitrogen atoms are quaternized with acetic acid. In this case, the polymeric cationic surfactant will have a weight average molecular weight of 600 to 60,000, preferably 600 to 1,800.
In another preferred embodiment, the transfer agent is a C$_2°-alkylamine which has been quaternized with citric acid, such as cetylarnine citrate.
e) Lecithins In the present context, the term lecithin includes compounds of the formulae (I) and (II) R'OCHz-CH-CHZ-O-P-OCHzCH2N(CH~), (I) O
and R30CH2-CH-CH,-O-P-O-CH,CHZNH3 (II) (7-in which R', Rz, R3, and R4 are each, independently of each other, a C,~_ZZ
saturated or unsaturated alkanoyl group, such as stearoyl, palmitoyl, oleoyl, palmitoleoyl, linoleoyl, linolenoyl, arachidonoyl, etc. Also useful in place of lecithins are lecithin-based compounds such as lyso-lecithins, in which RZ is replaced by hydrogen.
Lecithins are described in Kirk-Othmer EncXclopedia of Chemical Technolo~v, 3rd Ed., Wiley, New York, vol. 14, pp. 250-269 (1981), which is incorporated herein by reference.
In this embodiment, the.lecithin may but does not necessarily function as both the transfer agent and, according to the known art, as a skin care active agent. The Examples given below in which lecithin is used alone, in conjunction with waxy materials, demonstrate a physical protective barrier where lecithin functions as a transfer agent.
The following is a list of specific commercially available compounds which can be used as the transfer agent.
I. Primary Amines:
A. Alkyl Amines:
1. Armeen TD CAS 61790-33-8 AKZO
2. Armeen 18 CAS 124-30-1 AKZO
3. Armeen HT Flake CAS 61788-45-2 AKZO
4. Adogen 172-D CAS 112-90-3 Witco Oleoamine 5. ~do_g~n 185 CAS 686-10-26-4 Witco Etheramine (C12-15) 6. HexadecXl_amine CAS 143-27-1 Sigma-Aldrich II. Secondary Amines:
A. Dialkyl Amines:
1. Armeen 2HT CAS 61789-79-5 AKZO
H3C(CHZ)"NH(CHz)"CH3 2. Adogen 283 Ditridecylamine Witco III. Tertiary Amines:
A. Monoalkyl Dimethyl Amines:
1. AdQgen 340 (flaked) Trihydrogenated tallow amines Witco 2. Armeen DM 18D CAS 124-28-7 AKZO
B. Dialkyl Monomethyl Amines:
1. Adogen X49 CAS 4088-22-6 Witco Distearylmethylarriine 2. Armeen M2HT CAS 16788-63-4 AKZO
C. Trialkyl Amines:
1. Armeen 316 CAS 28947-77-5 AKZO
Trihexadecylamine D. Cyclic Amines:
1. Hexetidine 5-amino-1,3-bis(2-ethyl-hexyl)-5-methylhexa-hydropyrimidine Angus Chem. Co.
2. ~anguinarine HCl 13-methyl[1,3]benzodi-oxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridium Sigma/Aldrich IV. Mixed Primary and Secondary Amines:
A. Fatty Diamines:
1. Qdogen 570.5 CAS 61791-55-7 Witco Tallow 1,3-propylenediamine 2. Arosurf AA-57 CAS 68607-29-4 Witco V. Ethoxylated Amines:
1. Ethoduomeen CAS 61790-85-0 AKZO
2. Ethoduomeen C:AS 61790-85-0 AKZO
3, Eth_oduomegn CAS 61790-85-0 AKZO
4. l~thomeen 18/12CAS 10213-78-2 AKZO
VI. Amine Salts:
1. Duomeen TDO CAS 61791-53-5 AKZO
2. etylamine Hy~lrofluoride H3C(CH~),SNH3+F-(GABA #297) 3. prn~ ca I-~T CAS 61790-59-8 AKZO
VII. Polyamines:
A. Di- and Triamines:
1. Duomeen S CAS 61791-67-1 AKZO
2. Duomeen T CAS 61791-55-7 AKZO
HZN(CHZ),aNHz 1 S VIII. Quaternary Ammonium Salts:
A. Alkyltrimethyl Ammonium Salts:
1. C.~yhtr'~nethyl~~noniurn bromide CAS 57-09-0 Sigma-Aldrich 2. gtauad T-50 Tallow alkyltrimethyl ammonium bromide AKZO
B. Dialkyldimethyl Ammonium Salts:
1. Arq~ad 2HT-75 Bis(hydrogenated Tallow-alkyl)dimethyl ammonium chloride AKZO
_2 3-2. Bard,~,s; 2280 Didecyldimethyl ammonium chloride Lonza C. Trialkylmethyl Ammonium Salts:
1. Adog~en 316 Tricetylmethyl ammonium halide Witco $ 2. ~do~en 422 Behenyltrimethyl Ammonium chloride Witco D. Benzylalkyl:
1. Arpuad DMH TB-75 Dimethylbenzyl hydrogenat ed tallow ammonium chloride AKZO
2. B_~rr_a~,at MB- 80 Alkyldimethylbenzyl ammonium chloride Lonza IX. Imidazolinium Quats:
1. yarisoft 475 CAS 68122-86-1 Witco X. Pyridinium Quads:
A. Pyridinium Halides:
1. etyl_ Pvridinium Chloride XI. Polyelectrolytes:
A. Polymeric Quats:
1. Cat-Floc DL CAS 26062-79-3 Calgon Polydimethylallylammonium chloride 2. fat-Flo CAS 26062-79-3 Calgon Polydimethylallylammonium chloride 3. Cat-Floc T-2 CAS 26062-79-3 Calgon Polydimethylallyl ammonium chloride XII. Amphoteric Compounds:
A. Betain Derivatives:
1. ~ osol CG Coco amido betain Stepan 2. Amphosol CA Coco amido betain Stepan B. Proteins and related compounds with isoelectric points greater than physiologic pl-I (i.e., those which are positively charged when dissolved in body fluids).
1. Type A Gelatin 200 Proteins Kind-Knox 2. N N-Di-Methvlated Casein Methylated protein Sigma-Aldrich 3. Armeen Z CAS 68469-OS-08 AKZO
N-coco ~3 amidobutyric acid C. Lecthins 1. Lecithin (from e~~ ~ lkl. Phosphatidylcholine Sigma-Aldrich 2. T ecithin ~.,~,from soy beam Phosphatidylcholine Sigma-Aldrich 3. Lecithin (~Jltralecl Phosphatidylcholine Archer Daniels Midland 4. L~~thin (Yelkinoll Phosphatidylcholine Archer Daniels Midland WO 00!3$617 PCT/US99/30003 Natural Egg Yolk Phosphatidylcholine Source of lecithins: Grocery store TuF RA1t1Z1ER MATERIAL FUNCTION
Now having a mechanism for adhering a protective, hydrophobic material to the skin, any of several hydrophobic barrier materials may be selected to perform this function. A microcrystalline wax or a high molecular weight polydimethylsiloxane, for example, are barrier materiais which provide an adherent, conformal, hydrophobic, continuous, inert, colorless or near-colorless barrier. This hydrophobic waxy or polymeric barrier appears to endure in place and function indefinitely or until it is intentionally removed or sloughed off in the normal process of cellular turnover.
Thus, with the transfer and barrier functions performed, extended protection is provided against deleterious activities since the treated skin is coated and protected.
In use, the compositions of the present inventions are sprayed, brushed, or rubbed on the skin, even wet skin or skin immersed in water. Importantly, barrier materials are amorphous materials which shear or cleave easily so that materials which may adhere to the surface of the barrier may be removed easily by the application of moderate shear forces. This same low-shear characteristic moves the barrier materials about, exposing any active agent substances blended into the barrier materials.
Suitable barrier materials are disclosed in U.S. Patent No. 5,665,333 and U.S.
Patent 5,980,868, which are incorporated herein by reference in their entirety.
Hvdro~hobic Barrier Materials It has been found that various hydrophobic compounds of high molecular weight, solid at body temperature and generally similar to fats and waxes are useful as barrier forming materials. Typically they are long chain hydrocarbons, especially S normal paraffins having a chain length of 16 carbons or greater, paraffins with several loci of branching and unsaturation, where the extent of such branching and unsaturation does not lower the solidification point below body temperature, and show essentially no solubility in water or other aqueous materials. The major types of these wax-like materials belong to two basic categories:
I. Natural waxes of animal, vegetable or mineral origin such as beeswax, lanolin, spermaceti, carnauba wax, petroleum waxes including paraffin waxes, microcrystalline petrolatum and microcrystalline wax; and II. Synthetic materials including ethylenic polymers such as polyethylene glycols ("Carbowax"), polymethylene wax ("Paraflint") and various hydrocarbon I S types as obtained via Fisher-Tropsch synthesis.
Other suitable materials include silicone-based polymers such as polymethylalkylsiloxanes, polydimethylsiloxanes, poly(perfluoroalkylmethyl siloxanes), poly(methyl-3,3,3-trifluoropropyl siloxanes) and various aromatic (phenyl containing) siloxanes as sold by United Chemical.
_27_ Also useful are various fluoropolymers where some or all of the hydrogen is replaced by fluorine, including, among others: polytetrafluoroethylene (PTFE);
fluorinated polyethylene-propylene (FEP);
perfluoroalkoxy (PFA) polypropylene-polyethylene;
polyvinylidene fluoride (PVl~F); and polyvinylfluoride (PVF).
THE SKIN CARE ACTIVE AGENT FUNCTION
Experimentation with the technology of the present invention demonstrates that many materials known in the art of skin care to provide medical or cosmetic benefits to the skin may be incorporated into the composition of the present invention to enhance the known benefits of such skin care active agents. Through incorporation of known skin care active agents into compositions of the present invention, the known effects of such materials may be improved, by providing greater concentrations of the active agents to come into contact with the skin, by providing I 5 longer or extended contact of the active agent with the skin, by preventing removal of the active skin care agents by sweating, washing, swimming, or incidental contact, or by providing for more effective and efficient application of active skin care agents to wet skin, even to skin immersed under water.
In addition, some of the skin care agents tested and described in the Examples below migrated out or diffused away from the areas on which a Protective Coating (PC) was applied so that, to some extent, the skin care function extended to areas not reached by the PC itself. These skin care agents may be blended into the barrier material so that, as the barrier material is sheared, cleaved, disturbed, eroded, abraded, etc., fresh skin care agent is exposed and freed to function. Alternatively, certain undesirable or "side" effects of some skin care active agents, such as, for example, irritation, may be mitigated by incorporating the skin care active agent into the present invention, thus providing improved tolerance of the patient to the active agent.
Such skin care active.agents include, but are not limited to, Acetic Acid Aclometasone Dipropionate Acyclovir Alclometasone Dipropionatc Aluminum Chlorhydrate Aluminum Chlorhydroxide Aluminum Chloride Hexahydrate Amcinonide Aminobenzoate Potassium Ammonium Lactate Ammonium Mercury Amphotericin B
Anthralin Antimicrobial Agents Bacitracin Balsam Peru Benzocaine Benzoin Compoundecylenate Benzoyl Peroxide (BPO) Beta-Carotene Betamethasone Acetate Betamethasone Dipropionate Betamethasone Sodium Phosphate Betamethasone Valerate Butaconazole Nitrate Butamben Picrate Canthardin Carbol Fuchsin Castor Oil Cetylpyridinium Chloride Chloramphenicol Chlorcyclizine Chlorhexidine Chlorhexidine Acetate Chiorhexidine Gluconate Chloroxine Chloroxynol Ciclopirox Olamine Clindamycin HCl Clioquinol Clobetasol Propionate Clocortolone Pivalate C lotrimazole Coal Tar Collagenase Cortisone Cortisone Acetate Crotamiton Cyclopentolate HCl Dapsone Desonide Desoxymetasone Desoxyribonuclease Dexamethasone Dexamethasone Acetate Dexamethasone Sodium Phosphate Dibucaine Dichloroacetic Acid Dichlorophene Diflorasone Diacetate Diperodon Econazole Nitrate Ephedrine HCl Erythromycin Estradiol Etretinate Fibrinolysin Flucinolone Flucinolone Acetonide Fluocinonide Fluorouracil Fluradrenolone Flurandrenolide Fluticasone Propionate Formaldehyde Gentamycin Sulfate Gramicid Griseofulvin Guaifenesin Halcinonide Halobetasol Propionate Haloprogin Hexachlorophene Hexetadine Hyaluronidase Hydrocodone Hydrocortisone Hydrocortisone Acetate Hydrocortisone Butyrate Hydrocortisone Sodium Phosphate Hydrocortisone Sodium Succinate Hydrocortisone Valerate Hydroquinone Hydroxyzine HCl Hydroxyzine Pamoate Iodine Iodochlorhydrocodone Iodoquinol Isotretinoin Ketoconazole 1 S Lactic Acid Lecithin Lidocaine Hydrochloride Lindane Mafenide Acetate Meclocycline Sulfosalicylate Methoxsalen Methylprednisone Methylprednisone Acetate _33_ Methylprednisone Sodium Succinate Metronidazole Miconazole Nitrate Minoxidil Mometasone Furoate Monobenzone Mupriocin Naftifme HCl Neomycin Sulfate Nitrofurazone Nystatin Octyl Methoxycinnamate Oxybenzone Oxyquinoline Sulfate Papain para-Aminobenzoic Acid Permethrin Phentermine HCl Podophylum Polymyxin B Sulfate Potassium Iodide Pramoxine HCl Prednicarbate Prednisolone Sodium Phosphate Prednisone Pseudoephedrine Pyrogallic Acid Retinoic Acid Retinol Salicylic Acid Saluminum Acid Scarlet Red Selenium Sulfide Silver Nitrate Silver Sulfadiazine Sodium Sulfacetimide Sodium Thiosulfate Streptokinase Sulconazole Sulconazole Nitrate Sulfabenzamide Sulfacetamide Sulfanilamide Sulfathiazole Sulfur Sunscreen Agents _35_ Sutilains Terconazole Tetracaine Tetracycline Tretinoin Triacetin Triamcinolone Triamcinolone Acetonide Triamcinolone Diacetate Trimeprazine Tartrate Trioxsalen Triple Dye Trypsin Undecylenic Acid Urea Vitamins (all) Zinc Oxide Zinc Undecylenate and other agents known in the art to have medical, cosmetic, bactericidal, or other effects on the skin.
In addition, the present composition may also include coloring materials or fragrances to mask any color or odor of the other ingredients or to provide a more desirable appearance and smell. The fragrance or color may be present in an amount conventionally used for imparting the desired color or scent, typically 0.01 to 5 wt.%, preferably 0.1 to 1.0 wt.%, based on the total weight of the composition.
The present compositions may also include manufacturing aids, modifiers and thickeners, diluents, solvents, emulsifiers, stabilizers, and ingredients which enhance the aroma, appearance, opacity, color, texture, or any other attribute of the composition.
Thus, the present skin care compositions contain, at minimum, a barrier material, such as wax or other hydrophobic polymer, and at least 0.25 wt.% of a transfer agent, which is a compound having one region which is relatively hydrophobic, such as a hydrocarbon chain, and one portion which is positively charged under use conditions, such as a quaternary nitrogen. Anionic materials such as anionic surfactants can quantitatively neutralize a transfer agent by reacting with the positively charged group. Accordingly, addition of any quantity of an anionic surfactant to the present skin care composition will decrease the activity of the transfer agent, and, if enough anionic agent is present, the transfer agent will no longer function.
Thus, the present skin care compositions preferably contain at least U.25 wt.%
of transfer agent above and beyond the amount of transfer agent which is neutralized by any neutralizing anionic reagent also present in the composition (or, in alternative language, the present skin care compositions contain at least 0.25 wt.% of a transfer agent not including the amount of transfer agent which is neutralized by any neutralizing anionic reagent also present in the composition). More preferably, the present skin care compositions preferably contain at least 1 wt.% of transfer agent _37_ WO 00/38617 PCTlUS99/30003 above and beyond the amount of transfer agent which is neutralized by any neutralizing anionic reagent also present in the composition. Most preferably, anionic reagents of any kind should not be included in the present skin care composition unless provision is made to physically separate, for example, by encapsulation, the anionic reagent from the cationic transfer agent.
It should be realized that many anionic reagents contain more than one anionic functional group. In such cases, one mole of the anionic reagent may neutralize more than one mole of the transfer agent, and the amount of transfer agent which will be neutralized by the anionic reagent is calculated by taking into account the number of equivalents of anionic neutralizing groups contained in the anionic reagent.
Similarly, soluble compounds with anionic groups which may, for example, remain on the skin after washing with an anionic detergent, can decrease the effectiveness of the present skin care compositions by neutralizing or partially neutralizing the transfer agent. Ordinarily, however, the amount of soluble anionic reagents remaining on skin after washing and thoroughly rinsing will be so small (100- to 100,000-fold lower than the transfer agent) as to inactivate only a very small percentage of the transfer agent, thus having no material effect of the performance of the present skin care compositions.
In the context of the present invention, such anionic reagents include those compounds which contain anionic functional groups which can be thought of as being obtained by the neutralization of a strong acid, i.e., the neutralization of a sulfonic acid to obtain a sulfonate. Such anionic reagents, of course, include anionic surfactants. Anionic surfactants are disclosed in McCutcheon's~ Volume l:
Emulsifiers and Detergents, North American and International Editions, Pub. by McCutcheon's Division, The Manufacturing Confectioner Publishing Co., Glen Rock, NJ USA, which is incorporated herein by reference.
Particularly important classes of anionic surfactants include: sulfates, S sulfonates, oxysulfates, and ether sulfates of fatty acids, fatty acid esters, alcohols, and petroleum derivatives, their salts, their aryl, alkyl, and arylalkyl derivatives, and similar synthetic compounds, including but not limited to members of the following groups:
Comnou~l~. Manufacturer' Avirol series Henkel Abex series Rhone-Poulenc Barium Petronate seriesWitco Alpha-step Stepan Alox series Alox 1 S Actrasol series Climax Performance Chemicals Aristonate series Pilot Chemical Astromid series Alco Astrowet series Alco Arylenes Huntsman Avenel S series PPG
*Manufacturers addressed are listed in Mc(:utcheon's, reference cited above.
Sulfoccinates, including but not limited to members of the following groups:
Aerosol series Cytec Industries Carboxylated aryl, alkyl, and arylalkyl alcohols and their derivatives, including but not limited to members of the following groups:
Abex 3594 Rhone Poulenc Aryl, alkyl, and arylalkyl phosphate esters, their sodium salts, and derivatives, S including but not limited to members of the following groups:
Acrilev OJP Finetex Alkylene series Hart Products Actrafos Climax Amphisol series Givaudan-Roure Barisol series Dexter Fatty acid derivatives of organic acids, including but not limited to members of the following groups:
Amisoft series Ajinomoto USA
Protein based compounds and their derivatives, including but not limited to members of the following groups:
Aminofoam C Croda Atrasein 115 Atramax Organosilane and organosiloxane sulfates, sulfonates, thiosulfates, and their derivatives, including but not limited to members of the following groups:
Abil S-201 Goldschmidt The present compasitions may be prepared by a method in which the barner material is first suspended or dissolved in an appropriate solvent (e.g.
xylene, toluene, petroleum ether, methanol, ethanol, methyl ethyl ketone, or where, for example, aqueous dispersions of fluorocarbons are selected as barrier materials, water). The transfer agents) and, optionally, skin care agents) are then added and the solvent removed by, e.g., evaporation. The present compositions may also be prepared by direct mixing of the barrier material and the other ingredients, either stepwise or all together, at or above the melting point of the barrier material, if the other ingredients are stable or will tolerate for a sufficient time such a temperature.
As noted above, one embodiment of the present invention provides compositions which comprise lecithin. Lecithin is a naturally occurring group of phospholipids that is found in nearly every living cell. The food industry has long recognized lecithin as a lipophilic emulsifier used in products like margarine. and chocolate. Lecithin lends itself to specific modification techniques to extend the functionality and physical characteristics of lecithin far beyond their natural variations to include a wider range of functionalities such as dispersion, lubrication, and wetting which also involve enhanced specificity of bonding to oppositely charged surfaces.
For example, removing oily components, such as triglycerides and fatty acids, from lecithin a significant enhancement in positively charged components is realized.
Also as noted above, one embodiment of the present invention provides compositions which comprise chitosan. Such compositions provide an effective and practical approach to control skin problems in animals. A combined action of natural products such as chitosan and lecithin permits an effective delivery of a waxy barrier to the animal's skin on a continuous basis. Chitosan is a natural product derived from chitin, a polysaccharide found in the exoskeleton of shellfish like shrimp or crabs. It possesses many of the same properties as plant fibers, however, unlike plant fibers, it has the ability to bind fat significantly, acting as a "fat storage." Chitosan has been reported to have antibacterial properties and also to inhibit formation of plaque/tooth decay. Chitosan is derived from chitin by removing and refining the acetyl groups S through a process called de-acetylation. This process converts the neutral chitin molecules into molecules with a strong positive polarity. This positive polarity attracts the chitosan molecule to negatively charged surfaces by ionic interactions (similarly as a magnet attracts steel). Chitosan is commercially available from, e.g., Aldrich Chemical co. 1001 west St. Paul Ave., Milwaukee, WI 53233. A strong affinity of chitosan for fatty or waxy substances makes it an ideal matrix material to bind and confine the present compositions into a self cohesive and granular form easily incorporated into skin care formulations. The granular form of the final product is not tacky and is easy to handle.
The present method of application may be carried out by contacting the present composition with the skin to effect transfer of the composition to the skin. In a preferred embodiment, the present compositions are applied to human or animal dermis, epidermis, and/or stratum corneum. The exact means of contacting will depend of course on the nature of the composition and/or applicator. Thus, in the case of an atomizer, spraying will suffice to apply the compositions, while creams may be applied with a swab, brush, puff, or by hand.
Thus, the compositions may be applied to the skin to form a "breathable"
barrier which can effectively be applied to wet or dry skin to:
I . Produce cosmetically and medically desirable effects through the barrier function alone, without inclusion of a medicament, cosmetic, or other active ingredient; and 2. Carry known or yet to be discovered medicaments, cosmetic, or other active agents and hold them in contact with the skin in higher concentrations, and/or for extended periods of time, and/or in a more aesthetically desirable condition to provide performance superior to the same ingredients when applied to the skin via conventional vehicles.
Accordingly, the present compositions and methods may be used to prevent, treat, cure and relieve symptoms of diseases and conditions of the skin, internal and external membranes, mucosa, blood, lymphatic and other vessels and glomeruli of the body and its organs including systemic disease and conditions having primary or ancillary signs or symptoms manifesting in or on the skin, internal and external membranes, mucosa, blood, lymphatic and other vessels and glomeruli of the body and its organs, including but not limited to allergies, dermatitises, dermatoses, bacterial, fungal, and parasitic infestations and infections, abrasions, lacerations, cuts, burns, and other insults and injuries resulting from or related to injury or normal or abnormal metabolic, pathologic, or immunological processes. Such diseases and conditions include but are not limited to acne, athlete's foot, jock itch, ringworm, hemorrhoids, nail infections, skin infections, sunburn and sun- or injury-induced pigmentation, psoriasis, seborrhea, eczema and other dermatitises, dermatoses, and other diseases and pathological processes including kidney diseases, atherscleroses, etc. listed in Dorland's Illustrated Medical Dictionary, Stedman's Medical Dictionary, and other sources.
'The present compositions and methods are useful to minimize the appearance of skin imperfections, to help shed dry, damaged cells and unclog pores, to moisturize, exfoliate, and reveal younger-looking skin, to ameliorate and minimize the visible signs of aging, to ameliorate, minimize, and manage complexion problems, to gently peel away outer layers of dry, sun-damaged skin to expose younger looking skin, to leave skin smooth, soft, and refreshed, to ameliorate or minimize cosmetic problems associated with dry, sensitive, normal, combination-oily skin, to help control oily or problem-prone skin, to soothe the skin, improve skin texture, and restore moisture to the skin, to smooth fine lines in the skin, to even skin tones, to refine the texture of the skin, to improve and treat acne-prone skin, to protect against environmental skin aging, to lighten pigmented areas, and to enhance and accelerate the results achieved with other products.
Thus, the present composition may take the form of:
1. Makeup 2. Makeup Foundation 3. Makeup Remover 4. Eye Makeup 5. Eye Makeup Remover 6. Eye Makeup Pencil 7. Eye shadow 8. Facial Cream 9. Facial Cleanser 10. Facial Emulsion 11. Facial Mask 12. Facial Makeup S 13. Facial Scrub 14. Hand Cream 15. Body Cream 16. Sun Tan Lotion (including Sun Screen) 17. Lotion 18. Baby Oil 19. Baby Lotion 20. Anti-Aging Cream 21. Night Cream 22. Vanishing Cream 23. Cold Cream 24. Balm 25. Skin Conditioner 26. Disposable Wipe 27. Baby Wipe 28. Cleansing Cream 29. Lip Conditioner 30. Chap Preventative 31. Wound Care Ointment 32. Foundation for Lipstick (when applied to the lips before applying lipstick, the present composition locks or bonds the lipstick in place; no "feathering" or "bleeding" takes place and it looks as good 10 hours after application as it did just following application.) 33. Ingredient in Make-Up (lasts longer and goes on wet) 34. Anti-Perspirant/Deodorant 35. Wound Care (anti-adhesion, anti-infection, may contain antibiotic, e.g., Neosporin, ete.) 36. Surgical Site Wound Care 37. Implants (can provide anti-adhesion, anti-infection benefits when applied to the skin or tissues in contact with implants, e.g., pacemakers, etc. or on certain surfaces of the implant itself. Many conventional pacemaker implants produce infections which require removal and re-implantation. Application of the present composition to the skin or tissues in contact with the implant or on certain surfaces of the implant itself may prevent the adhesion of surrounding tissues to the implant, where desirable and also prevent or decrease the rate of infection, especially when the present composition comprises one or more anti-bacterial agents.
38. Indwelling Instruments (the present composition may provide anti-adhesion and anti-infection benefits when applied to the skin or tissues in contact with indwelling instruments, e.g., catheters, etc. or on certain surfaces of the indwelling instrument itself.) 39. Surgical Sites, Instruments, Sutures (coating surgical instruments andlor sutures with the present invention may provide anti-adhesion and anti-infection benefits and may reduce the resistance to placing the sutures by reducing the frictional resistance of the sutures.) 40. Athlete's Foot (the present invention even without an active agent may provide benefits; hexetidine is not only a preferred transfer agent but also a good anti-fungal material as well as a weak anti-bacterial material; thus, compositions which contain about 5% by weight hexetidine provide extended contact time with the affected area.) 41. Jock-Itch (jock-itch is caused by the same fungus responsible for athlete's foot and application of the present composition to the affected area may be effective for the prevention and/or treatment of jock-itch.) 42. Anti-Itch (the present compositions may be used as anti-itch compositions, even without inclusion of an active agent, especially when the itching is caused by external stimuli; traditional ani-itch agents, e.g., hydrocortizone may also be included in the present compositions.) 43. Diaper Rash (the present compositions may be applied to the affected area or to the diaper itself to combat diaper rash.) 44. Anti-Wrinkle Products (the present composition may be used to reduce wrinkles even without the presence of an active agent; alternatively, the present composition may contain an anti-wrinkle active agent such as shark liver oil.) _47_ 45. Anti-Anal Itch (the present composition may be applied to the affected area to combat anal itch even without an added active agent; traditional ani-itch agents, e.g., hydrocortizone may also be included in the present compositions;
the ability of the present compositions to adhere to moist surfaces means that it will stay in place longer and require fewer applications.) 46. Muscle Rub (compositions according to the present invention which contain a circulation-stimulating active agent, e.g., capsicum, etc. may be applied to the skin to treat sore or stiff muscles; the adherence of the present compositions to the skin means that the circulation-stimulating active agent (and resultant heat) will remain in contact with the affected area longer.) 47. Poison Oak, Ivy, Sumac, Etc. (the present compositions may be applied to the skin priox to engaging in activity which would bring the skin into contact with poisonous plants, e.g., poison ivy, poison oak, poison sumac, etc. and serve as a prophylactic barrier even without an active agent; the present compositions 1 S may also be applied to skin already suffering from poison ivy, poison oak, poison sumac, etc. to reduce the itching and spread of the condition with or without an anti-itching active agent.) 48. Depilatory Enhancer {hair absorbs moisture and is then more easily cut and/or removed; application of the present composition allows the depilatory to be applied when the hair is wet, thereby enhancing the cutting and/or removal of the hair.) 49. Anti-Drying (the present compositions may be used to form a protective barrier on the skin to prevent loss of moisture and/or oils from the skin.) 50. Other forms which will be apparent to those skilled in the art.
It should be understood that in the above-listed applications, the present composition may comprise either: (1) a transfer agent and a barrier material;
or (2) a transfer agent, barrier material, and active agent. In other words, for the applications listed above, good effects may be achieved even without the addition of an active agent, but in certain situations it may be advantageous and/or desirable to add an active agent.
The present compositions are typically applied to the skin in an amount effective to provide a protective barrier on the skin, usually about 80 micrograms to about 0.5 grams per cm2 of skin, preferably 100 micrograms to 0.1 grams per cm2 of skin.
Although the present invention has been described in detail in the context of skin care compositions and methods for treating the skin, the present compositions may be applied to substrates other than skin and may be used in methods other than I S skin care. In particular, it should be understood that the present compositions may be used in the following non-skin care applications.
Mold releases and casting adhesives. The release of a cast article from a mold may be enhanced by application of the present composition to the interior surface of the mold, or to the object to be cast or molded. This method may be especially effective for enhancing the release of a cast article made from a hydrophilic material {certain plastics and ceramics) from a mold which has a hydrophilic interior surface.
2. Ink and dye processing. The present compositions may be used to enhance the adherence of a hydrophobic ink to a hydrophilic substrate or vice-versa. In particular, the hydrophilic substrate may be coated with the present composition either aver the entire surface or in a patternwise fashion.
Application of the present composition to a hydrophilic surface may also be used to advantage in batik and tie-dye processes.
3. Anti-fouling applications. In marine applications, the present compositions may be applied to surfaces subject to fouling without hauling-out due to the ability of the present compositions to be applied to wet surfaces. The present compositions are useful as anti-fouling agents with or without active agents such as antibacterial agents. This is an important advantage, since most of the traditional anti-fouling materials, e.g., tin, copper, etc., are toxic to some marine organisms. When coated on a ship's hull, the present compositions may inhibit the attachment of marine growth to the hull or reduce the adherence of marine growth to the hull such that moving through the water at a speed of a few knots may be sufficient to remove any marine growth. In addition, the turbine blades of hydroelectric generators are plagued with fouling. Application of the present composition may be effective for reducing the fouling of turbine blades even in the face of the large shear forces encountered by turbine blades.
4. Leather treatments. Oils are destructive to leathers; they soften them and allow them to stretch and/or crack and they provide an attachment for grit and abrasives. Waxes are the preferred protectants. However, waxes applied -SO-directly to leathers are easily removed. Application of the present composition to leather provides extended benefits and reduced drying. In addition, since the outer layers slough off, less dirt will adhere to the leather.
5. Auto, vehicle protection. Application of the present composition to the interior and exterior surfaces of automobiles and other vehicles may be effective for protecting and/or enhancing the appearance and endurance or longevity of those surfaces. This may be especially effective for protecting hydrophilic surfaces such as certain seat coverings or other materials.
6. Wood protectant. W ood is negatively charged on the surface and contains moisture. The present compositions may thus be used as a furniture polish with excellent results, especially when rubbed down to a very thin but protective hydrophobic layer. The present compositions prevent water damage, e.g., water rings and stains. The present compositions may also be used to prevent wood from swelling, as in wood casement windows, and protect against mildew.
7. Metal treatments. The present compositions may be applied to metals to protect against oxidation, staining, chemical attack, and tarnishing.
8. Ceramic sealant. The present composition may be applied to certain ceramics to prevent and/or reduce the staining or fouling of the ceramic. For example, the present composition may be applied to showers, bathtubs, ceramic tile, and grout to prevent the formation of mold and mildew stains and bathtub rings.
9. Painted surfaces. The present composition may be applied to painted surfaces to afford a protective surface.
10. Floor wax. The present composition may be used as a floor wax, especially on floors with a hydrophilic surface, such as wood floors.
11. Anti-graffiti coatings. The present composition may be applied to surfaces which are subject to graffiti attacks, such as buildings, billboards, train cars, etc. The hydrophobic barrier afforded by the present composition not only makes it more difficult to apply the graffiti in the first place but also makes it easier to remove graffiti which is applied.
12. Paper and cardboard coatings. The present composition may be applied to paper or cardboard to obtain a moisture resistant barrier. This application may be useful not only for protecting the contents of a paper or cardboard package from water or moisture damage, but also for preparing a paper or cardboard package suitable for storing liquids such as milk or juice.
The materials used for covering the applicator-ends of the appliance may include, for example: a) natural or synthetic yarn, filaments, or other fibrous material either as such or assembled as a textile, or to any braided, stranded, woven, non-woven, knitted, matted, felted, etc. material, in which the materials of the composition of the present invention (hereinafter MCPI) are held among or between the fibers or the strands of the materials; b) foam-like or otherwise porous materials in which the MCPI are held within pores or apertures; or c) non-porous, non-fibrous materials such as some types of wood, plastic, metal, etc.
Thus, in one embodiment of the present invention, a single monolayer is composed of a low molecular weight transfer agent in which positively charged groups react with the negatively charged surfaces of the skin and the water repelling part of the hydrophobic chain forms a highly hydrophobic interface. Examples of such transfer agents are cetyltrimethylammonium bromide (CTAB), hexadecyltrimethylammonium bromide (HDTAB), 5-amino-1,3-bis(2-ethylhexyl)-5-methylhexahydro-5-methylpyrimidine (hexetidine) and various amines and quaternary amines, of which a good example is Hyamine-1622 quaternary amine.
The compositions of the present invention are generally liquid, semi-solid or solid state materials which may be applied to skin surfaces by hand, by pouring, by injection, or by flowing. For the compositions of the present invention to be applied -S-through the use of an atomizer, spray can, brush, wipe, cotton puff; roll-on device, or any other applicator or method of application by which liquid, semi-solid, or solid materials may be brought into contact with the skin, it may be necessary to modify the viscosity of the composition with suitable volatile solvents known in the art or to form emulsions by known means to provide formulations of appropriate viscosities.
The compositions of the present invention, as applied to the skin, provide a mufti-component protective coating (hereafter called the "Protective Coating:
or "PC"), as follows:
(1) The transfer agent component has dual functionality, being composed of materials having some molecular segments or parts of a polymeric chain which are positively charged and other such segments which exhibit hydrophobic characteristics.
(2) The barrier component is a hydrophobic, inert material (hereafter called the "barrier" material), such as a wax or polydimethylsiloxane which mixes with and adheres to the relatively uncharged, hydrophobic molecular segments or parts of the transfer agent molecule. The thickness of the barrier stratum is typically between about 1 and about 10 microns but can be thinner or thicker depending on the requirements of the particular application.
(3) Compositions of the present invention may optionally include one or more active agents which are intended to provide specific medical, cosmetic, or other effects according to the known art relating to such ingredients.
-(i-nFTAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Thus, in a first embodiment, the present invention provides novel compositions which comprise:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of one or more barrier materials.
Preferably, the present composition contains:
(a) 1 to 12 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 88 to 99 wt.%, based on the total weight of (a) and (b), of one or more barrier materials.
In a second embodiment, the present invention provides novel compositions which comprise:
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'~ 0.25 to 99.99 wt.%, based on the total weight of (b'~ and (b"'), of one or more transfer agents; and (b"') 0.01 to 99.75 wt.%, based on the total weight of (b'~ and (b"'), of one or more skin care agents, _7_ provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
Preferably, in this fifth embodiment, the present composition contains:
(a') 75 to 99 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 1 to 25 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'~ 1 to 99.9 wt.%, based on the total weight of (b'~ and (b"'), of one or more transfer agents; and (b"') 0.1 to 99 wt.%, based on the total weight of (b'~ and (b"'), of one or more skin care active agents, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
In a third embodiment, the present invention provides a method for forming a protective barrier on skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of transfer agent;
and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of a barner material.
Preferably, in this third embodiment, the present composition contains:
(a) 1 to 12 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and _g_ (b) 88 to 99 wt.%, based on the total weight of (a) and (b), of one or more barrier materials.
In a fourth embodiment, the present invention provides a method for cleaning and removing contamination from the skin while forming a protective barrier on skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of transfer agent; and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of a barrier material.
Preferably, in this fourth embodiment, the present composition contains:
(a) 1 to 12 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 88 to 99 wt.%, based on the total weight of (a) and (b), one or more barrier materials.
In a fifth embodiment, the present invention provides a method for applying a skin care agent to skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of ane or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'~ 0.25 to 99.99 wt.%, based on the total weight of (b'~ and (b"'), of one or more transfer agents; and (b"'} 0.01 to 99.75 wt.%, based on the total weight of (b'~ and (b"'), of at least one skin care agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
Preferably, in this fifth embodiment, the present composition contains:
(a') 75 to 99 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 1 to 25 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'~ 1 to 99.9 wt.%, based on the total weight of (b'~ and (b"'), of one or more transfer agents; and (b"') 0.1 to 99 wt.%, based on the total weight of (b'~ and (b"'), of one or more skin care active agents, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
In a sixth embodiment, the present invention provides a method for applying a skin care agent to the skin, which comprises applying to the skin a composition, said composition comprising:
(A) 5 to 90 wt.%, based on the total weight of (A) and (B), of one or more compositions described in the first or second embodiments; and (B) 10 to 95 wt.%, based on the total weight of (A) and (B), of one or more volatile diluents compatible with the other ingredients of the composition.
In a seventh embodiment, the present invention provides novel compositions which comprise:
(1) 25 to 80 wt.%, based on the total weight of {1), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water.
Preferably, in this seventh embodiment, the present composition contains:
(1) 30 to 60 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 10 to 40 wt.%, based on the total weight of (1), (2), and (3), of lecithin; and (3) 30 to 40 wt.%, based on the total weight of {1), (2), and (3), of water.
In an eighth embodiment, the present invention provides a method for applying a skin care agent to skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(1) 25 to 80 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water.
Preferably, in this eighth embodiment, the present composition contains:
(1) 30 to 60 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 10 to 40 wt.%, based on the total weight of (1), {2), and (3), of lecithin; and (3) 30 to 40 wt.%, based on the total weight of ( I ), (2), and (3), of water.
In an ninth embodiment, the present invention provides novel compositions which comprise:
{i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 1 to 50 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
Preferably, in this ninth embodiment, the present composition contains:
(i) S to 25 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 15 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 10 to 40 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
In a tenth embodiment, the present invention provides a method for applying a skin care agent to skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 1 to 50 wt.%, based on the total weight of (i), {ii), and (iii), of chitosan.
Preferably, in this tenth embodiment, the present composition comprises:
(i) 5 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
_ I 2-(ii) 15 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 10 to 40 wt.%, based on the total weight of (i), (ii), and {iii), of chitosan.
THE TRANSFER AGENT FUNCTION
To adhere a hydrophobic barrier material to the skin, especially to wet skin or skin immersed in water, a bi-functional transfer agent material is employed.
This material has some active groups which are electrostatically positively charged and some groups which are compatible with the hydrophobic materials of the barrier.
Useful transfer agent materials include various cetyl amine compounds, various diamines (including for example, Duomeens and Ethoduomeens), nitroparaffin-derived hetexocyclic amines, quaternary ammonium compounds, and the like. Also useful are compounds of certain cationic polyelectrolytes, including, for example, polyethyleneimine (PEI) derivatized with varying concentrations of fatty acids such as, for example, stearic acid, palmitic acid, oleic acid, etc.
Suitable transfer agents are disclosed in U.S. Patent Nos. 5,665,333, 5,888,480, 5,980,868, and 5,961,958 all of which are incorporated herein by reference in their entirety.
Transfer gent Materials:
Cationic transfer agent materials useful in the present invention are believed to attach to the skin via an electrostatic interaction between the cationic portion of the material and the negatively charged portion of the skin and thus predispose or condition the surface of the skin so that a waxy, hydrophobic material will then adhere to the surface. Transfer agent materials that are capable of strong electrostatic bonding to the negatively charged and hydrophilic surfaces of skin include various straight-chain alkylammonium compounds, cyclic alkylammonium compounds, petroleum derived cationics, lecithins, and the like.
a) Straight-chain alkylammonium compounds R' R' R' R-N-R" R-N+-H X- R-N~-R" X-R" R"' R represents a long (Cg_zo) alkyl chain which may be substituted with one or more hydroxy groups, R', R ", and R"' each independently may be either a long (CH_zo) alkyl chain which may be substituted with one or more hydroxy groups or a smaller (C,_4) alkyl groups which may be substituted with one or more hydroxy groups or aryl (C6_,o) groups or hydrogen, and X- represents an anion such as chloride or fluoride.
These schematic formulas are given for the purpose of defining the classes of compounds and represent the simplest concepts of cationic transfer agents whereby one or more hydrophobic alkyl groups are linked to a cationic nitrogen atom. In many instances the linkage is more complex as, for example, in RCONHCHZCHZCH,N(CH_3),. In addition, cationic transfer agents may contain more than one cationic nitrogen atom such as the following class of compounds RNHCHZCHZCHZNHZ and derivatives thereof.
Representative examples of compounds according to the above formulas are:
cetyl trimethylammonium bromide (CTAB), hexadecyltrimethylammonium bromide (HDTAB), stearyl dimethylbenzylammonium chloride, lauryl dimethylbenzylammonium chloride, cetyl dimethylethylammonium halide, cetyl dimethylbenzylammonium halide, cetyl trimethylammonium halide (bromide, chloride, fluoride), dodecyl ethyldimethylammonium halide, lauryl trimethylammonium halide, coconut aikyltrimethylammonium halide, N,N-C8_ZO-dialkyldimethylammonium halide, and specifically compounds such as bis(hydrogenated tallow alkyl) dimethylammonium chloride which is known to adsorb onto the surface with hydrophobic groups oriented away from it, 2-hydroxydodecyl-2-hydroxyethyl dimethyl ammonium chloride and N-octadecyl-N,N',N'-tris-(2-hydroxyethyl)-1,3-diaminopropane dihydrofluoride.
b) Cyclic Alkylammonium Compounds A further preferred group of compounds of the present invention which have been found to be applicable includes a class of surface-active quaternary ammonium compounds in which the nitrogen atom carrying the cationic charge is part of a heterocyclic ring. Suitable compounds, for example, are as follows:
laurylpyridinium chloride or bromide, tetradecylpyridinium bromide, cetylpyridinium halide (chloride, bromide or fluoride).
5-amino-1,3-bis(2-ethylhexyl)-5-methylhexahydro-5-methylpyrimidine (hexetidine) c) Petroleum Derived Cationics Typical basic amines are derived from petroleum-based raw materials such as olefins, paraffins, and aromatic hydrocarbons and include compounds with at least one aliphatic carbon chain containing six or more carbon atoms attached to the nitrogen.
Thus, amine salts, diamines, amidoamines, alkoxylated amines, and their respective quaternary salts are applicable.
Preferred compounds of this type include tallow or coco alkyl substituted 1,3-propylene diamines sold by Witco under the trade names of "Adogen" and "Emcol"
and similar diamines sold by Akzo under the trade name "Duomeen" and their polyethenoxy derivatives under the trade names of "Ethomeen" and "Ethoduomeens".
d) Polymeric Amines Suitable polymeric amines comprise a class of polymers containing ionic groups along the backbone chain and exhibit properties of both electrolytes and polymers. These materials contain nitrogen, of primary, secondary, tertiary or quaternary functionality in their backbone and may have weight average molecular weights as low as about 100 or higher than about 100,000. Representative of these polymeric cationic transfer agents are the following:
polydimeryl polyamine (General Mills Chemical Co.), polyamide (trade name "Versamide"), polyacrylamides, polydiallyldimethylammonium chloride ("Cat-Floc"), polyhexamethylene biguanide compounds as sold under the trade name "Vantocil", and also other biguanides, for example those disclosed in LJ.S. Patent Nos. 2,684,924, 2,990,425, 3,183,230, S 3,468,898, 4,022,834, 4,053,636 and 4,198,425, 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide ("Polybrene" from Aldrich), polyvinylpyrrolidone and their derivatives, polypeptides, poly(allylamine) hydrochloride, polyoxyethylenated amines, and specifically, polyethyleneimine ("Polymin" from BASF), and a class of related and surface active cationic polymers prepared by converting a fraction of the amino groups to their acyl derivatives. The polyethyleneimine is first condensed with less than the stoichiometric quantity of acid halides thus alkylating some of the amino groups and the remaining amino groups are then condensed with hydrogen halides such as hydrogen chloride or, preferentially, hydrogen fluoride. The surface activity of these compounds vary with the number of amino groups which are acylated, and with the chain length of the acylating group RCO-. The condensation reaction is typically performed with stearic or oleic acid chlorides in the presence of a solvent containing metal fluoride, preferentially silver fluoride, in such a manner that silver chloride formed in the reaction precipitates from the solvent, as described in _17_ Example XV of U.S. Patent No. 5,665,333, which is incorporated herein by reference in its entirety.
Also suitable, for the purpose of this invention, are cationic derivatives of polysaccharides such as dextran, starch or cellulose, for example, diethylaminoethyl cellulose ("DEAE-cellulose"). Examples of applicable copolymers based on acrylamide and a cationic monomer are available commercially under the trade name RETEN from Hercules Inc., or under the name FLOC AID from National Adhesives.
Particular examples of such polymers are FLOC AID 305 and RETEN 220. Similarly useful are acrylamide-based polyelectrolytes as sold by Allied Colloids under the trade name PERCOL. Further examples of suitable materials are the cationic guar derivatives such as those sold under the trade name JAGUAR by Celanese-Hall.
A further preferred group of compounds which comprises a class of water-insoluble polymers, having nitrogen atoms in their molecules, are quaternary polymers of quaternary ammonium type, betaine type, pyridylpyridinium type or vinylpyridinium type. Examples are as follows;
poly(vinyl-benzylmethyllaurylammonium chloride), poly(vinyl-benzylstearylbetaine), poly(vinyl-benzyllaurylpyridylpyridinium chloride), poly(vinyl-benzylcetylammonylhexyl ether) and quaternized polyoxyethyleneated long chain amines, with the general formula RN(CH3)[(CZHqO)xH]2{+) A(-), where A{-) is generally chloride or fluoride, x is a number from 1 to 20, and R is CR_2~-alkyl.
These cationic materials, by reacting with the surface of the skin, produce strongly hydrophobic films onto which hydrophobic barrier materials are easily transferred by brushing, rubbing, smearing, or burnishing.
It is important that the reason for this transferability be understood. The surface of human skin is normally hydrophilic and negatively charged. The transfer and adhesion of the barrier materials onto such surfaces is difficult or practically impossible unless the surface is modified by a material that is hydrophobic and therefore compatible with the barrier materials.
In a preferred embodiment, the transfer agent, a cationic surfactant, is a polymer which contains a nitrogen atom in a repeating unit and in which a portion of the nitrogen atoms are quaternized by formation of a salt with a C8_ZO fatty acid, preferably a C,2_zo fatty acid. Examples of such polymeric cationic surfactants include polyacrylamides, polyvinylpyridines, or polyamines, e.g., poly(ethyleneimine), in which from 5 to 95 mole%, preferably 40 to 60 mole%, of the nitrogen atoms have been quaternized by formation of a salt with a fatty acid. Typically such polymers will have a weight average molecular weight of 600 to 60,000, preferably 600 to 1,800.
In a another embodiment, the transfer agent is a polymer which contains a nitrogen atom in a repeating unit and in which a first portion of the nitrogen atoms are quaternized with a C8_Z° fatty acid, preferably a C,,_ZO fatty acid, and a second portion of the nitrogen atoms are quaternized by forming a salt with various acids such as hydrofluoric acid, etc. Examples of such polymeric cationic surfactants include polyacrylamides, polyvinylpyridines or polyamines, e.g., poly(ethyleneimine), in which from 5 to 95 mole%, preferably from 40 to 60 mole %, of the nitrogen atoms are converted to their acid derivatives by reaction with stearic or oleic acid chlorides, and from S to 95 mole%, preferably from 40 to 60 mole%, of the nitrogen atoms are quaternized with acetic acid. In this case, the polymeric cationic surfactant will have a weight average molecular weight of 600 to 60,000, preferably 600 to 1,800.
In another preferred embodiment, the transfer agent is a C$_2°-alkylamine which has been quaternized with citric acid, such as cetylarnine citrate.
e) Lecithins In the present context, the term lecithin includes compounds of the formulae (I) and (II) R'OCHz-CH-CHZ-O-P-OCHzCH2N(CH~), (I) O
and R30CH2-CH-CH,-O-P-O-CH,CHZNH3 (II) (7-in which R', Rz, R3, and R4 are each, independently of each other, a C,~_ZZ
saturated or unsaturated alkanoyl group, such as stearoyl, palmitoyl, oleoyl, palmitoleoyl, linoleoyl, linolenoyl, arachidonoyl, etc. Also useful in place of lecithins are lecithin-based compounds such as lyso-lecithins, in which RZ is replaced by hydrogen.
Lecithins are described in Kirk-Othmer EncXclopedia of Chemical Technolo~v, 3rd Ed., Wiley, New York, vol. 14, pp. 250-269 (1981), which is incorporated herein by reference.
In this embodiment, the.lecithin may but does not necessarily function as both the transfer agent and, according to the known art, as a skin care active agent. The Examples given below in which lecithin is used alone, in conjunction with waxy materials, demonstrate a physical protective barrier where lecithin functions as a transfer agent.
The following is a list of specific commercially available compounds which can be used as the transfer agent.
I. Primary Amines:
A. Alkyl Amines:
1. Armeen TD CAS 61790-33-8 AKZO
2. Armeen 18 CAS 124-30-1 AKZO
3. Armeen HT Flake CAS 61788-45-2 AKZO
4. Adogen 172-D CAS 112-90-3 Witco Oleoamine 5. ~do_g~n 185 CAS 686-10-26-4 Witco Etheramine (C12-15) 6. HexadecXl_amine CAS 143-27-1 Sigma-Aldrich II. Secondary Amines:
A. Dialkyl Amines:
1. Armeen 2HT CAS 61789-79-5 AKZO
H3C(CHZ)"NH(CHz)"CH3 2. Adogen 283 Ditridecylamine Witco III. Tertiary Amines:
A. Monoalkyl Dimethyl Amines:
1. AdQgen 340 (flaked) Trihydrogenated tallow amines Witco 2. Armeen DM 18D CAS 124-28-7 AKZO
B. Dialkyl Monomethyl Amines:
1. Adogen X49 CAS 4088-22-6 Witco Distearylmethylarriine 2. Armeen M2HT CAS 16788-63-4 AKZO
C. Trialkyl Amines:
1. Armeen 316 CAS 28947-77-5 AKZO
Trihexadecylamine D. Cyclic Amines:
1. Hexetidine 5-amino-1,3-bis(2-ethyl-hexyl)-5-methylhexa-hydropyrimidine Angus Chem. Co.
2. ~anguinarine HCl 13-methyl[1,3]benzodi-oxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridium Sigma/Aldrich IV. Mixed Primary and Secondary Amines:
A. Fatty Diamines:
1. Qdogen 570.5 CAS 61791-55-7 Witco Tallow 1,3-propylenediamine 2. Arosurf AA-57 CAS 68607-29-4 Witco V. Ethoxylated Amines:
1. Ethoduomeen CAS 61790-85-0 AKZO
2. Ethoduomeen C:AS 61790-85-0 AKZO
3, Eth_oduomegn CAS 61790-85-0 AKZO
4. l~thomeen 18/12CAS 10213-78-2 AKZO
VI. Amine Salts:
1. Duomeen TDO CAS 61791-53-5 AKZO
2. etylamine Hy~lrofluoride H3C(CH~),SNH3+F-(GABA #297) 3. prn~ ca I-~T CAS 61790-59-8 AKZO
VII. Polyamines:
A. Di- and Triamines:
1. Duomeen S CAS 61791-67-1 AKZO
2. Duomeen T CAS 61791-55-7 AKZO
HZN(CHZ),aNHz 1 S VIII. Quaternary Ammonium Salts:
A. Alkyltrimethyl Ammonium Salts:
1. C.~yhtr'~nethyl~~noniurn bromide CAS 57-09-0 Sigma-Aldrich 2. gtauad T-50 Tallow alkyltrimethyl ammonium bromide AKZO
B. Dialkyldimethyl Ammonium Salts:
1. Arq~ad 2HT-75 Bis(hydrogenated Tallow-alkyl)dimethyl ammonium chloride AKZO
_2 3-2. Bard,~,s; 2280 Didecyldimethyl ammonium chloride Lonza C. Trialkylmethyl Ammonium Salts:
1. Adog~en 316 Tricetylmethyl ammonium halide Witco $ 2. ~do~en 422 Behenyltrimethyl Ammonium chloride Witco D. Benzylalkyl:
1. Arpuad DMH TB-75 Dimethylbenzyl hydrogenat ed tallow ammonium chloride AKZO
2. B_~rr_a~,at MB- 80 Alkyldimethylbenzyl ammonium chloride Lonza IX. Imidazolinium Quats:
1. yarisoft 475 CAS 68122-86-1 Witco X. Pyridinium Quads:
A. Pyridinium Halides:
1. etyl_ Pvridinium Chloride XI. Polyelectrolytes:
A. Polymeric Quats:
1. Cat-Floc DL CAS 26062-79-3 Calgon Polydimethylallylammonium chloride 2. fat-Flo CAS 26062-79-3 Calgon Polydimethylallylammonium chloride 3. Cat-Floc T-2 CAS 26062-79-3 Calgon Polydimethylallyl ammonium chloride XII. Amphoteric Compounds:
A. Betain Derivatives:
1. ~ osol CG Coco amido betain Stepan 2. Amphosol CA Coco amido betain Stepan B. Proteins and related compounds with isoelectric points greater than physiologic pl-I (i.e., those which are positively charged when dissolved in body fluids).
1. Type A Gelatin 200 Proteins Kind-Knox 2. N N-Di-Methvlated Casein Methylated protein Sigma-Aldrich 3. Armeen Z CAS 68469-OS-08 AKZO
N-coco ~3 amidobutyric acid C. Lecthins 1. Lecithin (from e~~ ~ lkl. Phosphatidylcholine Sigma-Aldrich 2. T ecithin ~.,~,from soy beam Phosphatidylcholine Sigma-Aldrich 3. Lecithin (~Jltralecl Phosphatidylcholine Archer Daniels Midland 4. L~~thin (Yelkinoll Phosphatidylcholine Archer Daniels Midland WO 00!3$617 PCT/US99/30003 Natural Egg Yolk Phosphatidylcholine Source of lecithins: Grocery store TuF RA1t1Z1ER MATERIAL FUNCTION
Now having a mechanism for adhering a protective, hydrophobic material to the skin, any of several hydrophobic barrier materials may be selected to perform this function. A microcrystalline wax or a high molecular weight polydimethylsiloxane, for example, are barrier materiais which provide an adherent, conformal, hydrophobic, continuous, inert, colorless or near-colorless barrier. This hydrophobic waxy or polymeric barrier appears to endure in place and function indefinitely or until it is intentionally removed or sloughed off in the normal process of cellular turnover.
Thus, with the transfer and barrier functions performed, extended protection is provided against deleterious activities since the treated skin is coated and protected.
In use, the compositions of the present inventions are sprayed, brushed, or rubbed on the skin, even wet skin or skin immersed in water. Importantly, barrier materials are amorphous materials which shear or cleave easily so that materials which may adhere to the surface of the barrier may be removed easily by the application of moderate shear forces. This same low-shear characteristic moves the barrier materials about, exposing any active agent substances blended into the barrier materials.
Suitable barrier materials are disclosed in U.S. Patent No. 5,665,333 and U.S.
Patent 5,980,868, which are incorporated herein by reference in their entirety.
Hvdro~hobic Barrier Materials It has been found that various hydrophobic compounds of high molecular weight, solid at body temperature and generally similar to fats and waxes are useful as barrier forming materials. Typically they are long chain hydrocarbons, especially S normal paraffins having a chain length of 16 carbons or greater, paraffins with several loci of branching and unsaturation, where the extent of such branching and unsaturation does not lower the solidification point below body temperature, and show essentially no solubility in water or other aqueous materials. The major types of these wax-like materials belong to two basic categories:
I. Natural waxes of animal, vegetable or mineral origin such as beeswax, lanolin, spermaceti, carnauba wax, petroleum waxes including paraffin waxes, microcrystalline petrolatum and microcrystalline wax; and II. Synthetic materials including ethylenic polymers such as polyethylene glycols ("Carbowax"), polymethylene wax ("Paraflint") and various hydrocarbon I S types as obtained via Fisher-Tropsch synthesis.
Other suitable materials include silicone-based polymers such as polymethylalkylsiloxanes, polydimethylsiloxanes, poly(perfluoroalkylmethyl siloxanes), poly(methyl-3,3,3-trifluoropropyl siloxanes) and various aromatic (phenyl containing) siloxanes as sold by United Chemical.
_27_ Also useful are various fluoropolymers where some or all of the hydrogen is replaced by fluorine, including, among others: polytetrafluoroethylene (PTFE);
fluorinated polyethylene-propylene (FEP);
perfluoroalkoxy (PFA) polypropylene-polyethylene;
polyvinylidene fluoride (PVl~F); and polyvinylfluoride (PVF).
THE SKIN CARE ACTIVE AGENT FUNCTION
Experimentation with the technology of the present invention demonstrates that many materials known in the art of skin care to provide medical or cosmetic benefits to the skin may be incorporated into the composition of the present invention to enhance the known benefits of such skin care active agents. Through incorporation of known skin care active agents into compositions of the present invention, the known effects of such materials may be improved, by providing greater concentrations of the active agents to come into contact with the skin, by providing I 5 longer or extended contact of the active agent with the skin, by preventing removal of the active skin care agents by sweating, washing, swimming, or incidental contact, or by providing for more effective and efficient application of active skin care agents to wet skin, even to skin immersed under water.
In addition, some of the skin care agents tested and described in the Examples below migrated out or diffused away from the areas on which a Protective Coating (PC) was applied so that, to some extent, the skin care function extended to areas not reached by the PC itself. These skin care agents may be blended into the barrier material so that, as the barrier material is sheared, cleaved, disturbed, eroded, abraded, etc., fresh skin care agent is exposed and freed to function. Alternatively, certain undesirable or "side" effects of some skin care active agents, such as, for example, irritation, may be mitigated by incorporating the skin care active agent into the present invention, thus providing improved tolerance of the patient to the active agent.
Such skin care active.agents include, but are not limited to, Acetic Acid Aclometasone Dipropionate Acyclovir Alclometasone Dipropionatc Aluminum Chlorhydrate Aluminum Chlorhydroxide Aluminum Chloride Hexahydrate Amcinonide Aminobenzoate Potassium Ammonium Lactate Ammonium Mercury Amphotericin B
Anthralin Antimicrobial Agents Bacitracin Balsam Peru Benzocaine Benzoin Compoundecylenate Benzoyl Peroxide (BPO) Beta-Carotene Betamethasone Acetate Betamethasone Dipropionate Betamethasone Sodium Phosphate Betamethasone Valerate Butaconazole Nitrate Butamben Picrate Canthardin Carbol Fuchsin Castor Oil Cetylpyridinium Chloride Chloramphenicol Chlorcyclizine Chlorhexidine Chlorhexidine Acetate Chiorhexidine Gluconate Chloroxine Chloroxynol Ciclopirox Olamine Clindamycin HCl Clioquinol Clobetasol Propionate Clocortolone Pivalate C lotrimazole Coal Tar Collagenase Cortisone Cortisone Acetate Crotamiton Cyclopentolate HCl Dapsone Desonide Desoxymetasone Desoxyribonuclease Dexamethasone Dexamethasone Acetate Dexamethasone Sodium Phosphate Dibucaine Dichloroacetic Acid Dichlorophene Diflorasone Diacetate Diperodon Econazole Nitrate Ephedrine HCl Erythromycin Estradiol Etretinate Fibrinolysin Flucinolone Flucinolone Acetonide Fluocinonide Fluorouracil Fluradrenolone Flurandrenolide Fluticasone Propionate Formaldehyde Gentamycin Sulfate Gramicid Griseofulvin Guaifenesin Halcinonide Halobetasol Propionate Haloprogin Hexachlorophene Hexetadine Hyaluronidase Hydrocodone Hydrocortisone Hydrocortisone Acetate Hydrocortisone Butyrate Hydrocortisone Sodium Phosphate Hydrocortisone Sodium Succinate Hydrocortisone Valerate Hydroquinone Hydroxyzine HCl Hydroxyzine Pamoate Iodine Iodochlorhydrocodone Iodoquinol Isotretinoin Ketoconazole 1 S Lactic Acid Lecithin Lidocaine Hydrochloride Lindane Mafenide Acetate Meclocycline Sulfosalicylate Methoxsalen Methylprednisone Methylprednisone Acetate _33_ Methylprednisone Sodium Succinate Metronidazole Miconazole Nitrate Minoxidil Mometasone Furoate Monobenzone Mupriocin Naftifme HCl Neomycin Sulfate Nitrofurazone Nystatin Octyl Methoxycinnamate Oxybenzone Oxyquinoline Sulfate Papain para-Aminobenzoic Acid Permethrin Phentermine HCl Podophylum Polymyxin B Sulfate Potassium Iodide Pramoxine HCl Prednicarbate Prednisolone Sodium Phosphate Prednisone Pseudoephedrine Pyrogallic Acid Retinoic Acid Retinol Salicylic Acid Saluminum Acid Scarlet Red Selenium Sulfide Silver Nitrate Silver Sulfadiazine Sodium Sulfacetimide Sodium Thiosulfate Streptokinase Sulconazole Sulconazole Nitrate Sulfabenzamide Sulfacetamide Sulfanilamide Sulfathiazole Sulfur Sunscreen Agents _35_ Sutilains Terconazole Tetracaine Tetracycline Tretinoin Triacetin Triamcinolone Triamcinolone Acetonide Triamcinolone Diacetate Trimeprazine Tartrate Trioxsalen Triple Dye Trypsin Undecylenic Acid Urea Vitamins (all) Zinc Oxide Zinc Undecylenate and other agents known in the art to have medical, cosmetic, bactericidal, or other effects on the skin.
In addition, the present composition may also include coloring materials or fragrances to mask any color or odor of the other ingredients or to provide a more desirable appearance and smell. The fragrance or color may be present in an amount conventionally used for imparting the desired color or scent, typically 0.01 to 5 wt.%, preferably 0.1 to 1.0 wt.%, based on the total weight of the composition.
The present compositions may also include manufacturing aids, modifiers and thickeners, diluents, solvents, emulsifiers, stabilizers, and ingredients which enhance the aroma, appearance, opacity, color, texture, or any other attribute of the composition.
Thus, the present skin care compositions contain, at minimum, a barrier material, such as wax or other hydrophobic polymer, and at least 0.25 wt.% of a transfer agent, which is a compound having one region which is relatively hydrophobic, such as a hydrocarbon chain, and one portion which is positively charged under use conditions, such as a quaternary nitrogen. Anionic materials such as anionic surfactants can quantitatively neutralize a transfer agent by reacting with the positively charged group. Accordingly, addition of any quantity of an anionic surfactant to the present skin care composition will decrease the activity of the transfer agent, and, if enough anionic agent is present, the transfer agent will no longer function.
Thus, the present skin care compositions preferably contain at least U.25 wt.%
of transfer agent above and beyond the amount of transfer agent which is neutralized by any neutralizing anionic reagent also present in the composition (or, in alternative language, the present skin care compositions contain at least 0.25 wt.% of a transfer agent not including the amount of transfer agent which is neutralized by any neutralizing anionic reagent also present in the composition). More preferably, the present skin care compositions preferably contain at least 1 wt.% of transfer agent _37_ WO 00/38617 PCTlUS99/30003 above and beyond the amount of transfer agent which is neutralized by any neutralizing anionic reagent also present in the composition. Most preferably, anionic reagents of any kind should not be included in the present skin care composition unless provision is made to physically separate, for example, by encapsulation, the anionic reagent from the cationic transfer agent.
It should be realized that many anionic reagents contain more than one anionic functional group. In such cases, one mole of the anionic reagent may neutralize more than one mole of the transfer agent, and the amount of transfer agent which will be neutralized by the anionic reagent is calculated by taking into account the number of equivalents of anionic neutralizing groups contained in the anionic reagent.
Similarly, soluble compounds with anionic groups which may, for example, remain on the skin after washing with an anionic detergent, can decrease the effectiveness of the present skin care compositions by neutralizing or partially neutralizing the transfer agent. Ordinarily, however, the amount of soluble anionic reagents remaining on skin after washing and thoroughly rinsing will be so small (100- to 100,000-fold lower than the transfer agent) as to inactivate only a very small percentage of the transfer agent, thus having no material effect of the performance of the present skin care compositions.
In the context of the present invention, such anionic reagents include those compounds which contain anionic functional groups which can be thought of as being obtained by the neutralization of a strong acid, i.e., the neutralization of a sulfonic acid to obtain a sulfonate. Such anionic reagents, of course, include anionic surfactants. Anionic surfactants are disclosed in McCutcheon's~ Volume l:
Emulsifiers and Detergents, North American and International Editions, Pub. by McCutcheon's Division, The Manufacturing Confectioner Publishing Co., Glen Rock, NJ USA, which is incorporated herein by reference.
Particularly important classes of anionic surfactants include: sulfates, S sulfonates, oxysulfates, and ether sulfates of fatty acids, fatty acid esters, alcohols, and petroleum derivatives, their salts, their aryl, alkyl, and arylalkyl derivatives, and similar synthetic compounds, including but not limited to members of the following groups:
Comnou~l~. Manufacturer' Avirol series Henkel Abex series Rhone-Poulenc Barium Petronate seriesWitco Alpha-step Stepan Alox series Alox 1 S Actrasol series Climax Performance Chemicals Aristonate series Pilot Chemical Astromid series Alco Astrowet series Alco Arylenes Huntsman Avenel S series PPG
*Manufacturers addressed are listed in Mc(:utcheon's, reference cited above.
Sulfoccinates, including but not limited to members of the following groups:
Aerosol series Cytec Industries Carboxylated aryl, alkyl, and arylalkyl alcohols and their derivatives, including but not limited to members of the following groups:
Abex 3594 Rhone Poulenc Aryl, alkyl, and arylalkyl phosphate esters, their sodium salts, and derivatives, S including but not limited to members of the following groups:
Acrilev OJP Finetex Alkylene series Hart Products Actrafos Climax Amphisol series Givaudan-Roure Barisol series Dexter Fatty acid derivatives of organic acids, including but not limited to members of the following groups:
Amisoft series Ajinomoto USA
Protein based compounds and their derivatives, including but not limited to members of the following groups:
Aminofoam C Croda Atrasein 115 Atramax Organosilane and organosiloxane sulfates, sulfonates, thiosulfates, and their derivatives, including but not limited to members of the following groups:
Abil S-201 Goldschmidt The present compasitions may be prepared by a method in which the barner material is first suspended or dissolved in an appropriate solvent (e.g.
xylene, toluene, petroleum ether, methanol, ethanol, methyl ethyl ketone, or where, for example, aqueous dispersions of fluorocarbons are selected as barrier materials, water). The transfer agents) and, optionally, skin care agents) are then added and the solvent removed by, e.g., evaporation. The present compositions may also be prepared by direct mixing of the barrier material and the other ingredients, either stepwise or all together, at or above the melting point of the barrier material, if the other ingredients are stable or will tolerate for a sufficient time such a temperature.
As noted above, one embodiment of the present invention provides compositions which comprise lecithin. Lecithin is a naturally occurring group of phospholipids that is found in nearly every living cell. The food industry has long recognized lecithin as a lipophilic emulsifier used in products like margarine. and chocolate. Lecithin lends itself to specific modification techniques to extend the functionality and physical characteristics of lecithin far beyond their natural variations to include a wider range of functionalities such as dispersion, lubrication, and wetting which also involve enhanced specificity of bonding to oppositely charged surfaces.
For example, removing oily components, such as triglycerides and fatty acids, from lecithin a significant enhancement in positively charged components is realized.
Also as noted above, one embodiment of the present invention provides compositions which comprise chitosan. Such compositions provide an effective and practical approach to control skin problems in animals. A combined action of natural products such as chitosan and lecithin permits an effective delivery of a waxy barrier to the animal's skin on a continuous basis. Chitosan is a natural product derived from chitin, a polysaccharide found in the exoskeleton of shellfish like shrimp or crabs. It possesses many of the same properties as plant fibers, however, unlike plant fibers, it has the ability to bind fat significantly, acting as a "fat storage." Chitosan has been reported to have antibacterial properties and also to inhibit formation of plaque/tooth decay. Chitosan is derived from chitin by removing and refining the acetyl groups S through a process called de-acetylation. This process converts the neutral chitin molecules into molecules with a strong positive polarity. This positive polarity attracts the chitosan molecule to negatively charged surfaces by ionic interactions (similarly as a magnet attracts steel). Chitosan is commercially available from, e.g., Aldrich Chemical co. 1001 west St. Paul Ave., Milwaukee, WI 53233. A strong affinity of chitosan for fatty or waxy substances makes it an ideal matrix material to bind and confine the present compositions into a self cohesive and granular form easily incorporated into skin care formulations. The granular form of the final product is not tacky and is easy to handle.
The present method of application may be carried out by contacting the present composition with the skin to effect transfer of the composition to the skin. In a preferred embodiment, the present compositions are applied to human or animal dermis, epidermis, and/or stratum corneum. The exact means of contacting will depend of course on the nature of the composition and/or applicator. Thus, in the case of an atomizer, spraying will suffice to apply the compositions, while creams may be applied with a swab, brush, puff, or by hand.
Thus, the compositions may be applied to the skin to form a "breathable"
barrier which can effectively be applied to wet or dry skin to:
I . Produce cosmetically and medically desirable effects through the barrier function alone, without inclusion of a medicament, cosmetic, or other active ingredient; and 2. Carry known or yet to be discovered medicaments, cosmetic, or other active agents and hold them in contact with the skin in higher concentrations, and/or for extended periods of time, and/or in a more aesthetically desirable condition to provide performance superior to the same ingredients when applied to the skin via conventional vehicles.
Accordingly, the present compositions and methods may be used to prevent, treat, cure and relieve symptoms of diseases and conditions of the skin, internal and external membranes, mucosa, blood, lymphatic and other vessels and glomeruli of the body and its organs including systemic disease and conditions having primary or ancillary signs or symptoms manifesting in or on the skin, internal and external membranes, mucosa, blood, lymphatic and other vessels and glomeruli of the body and its organs, including but not limited to allergies, dermatitises, dermatoses, bacterial, fungal, and parasitic infestations and infections, abrasions, lacerations, cuts, burns, and other insults and injuries resulting from or related to injury or normal or abnormal metabolic, pathologic, or immunological processes. Such diseases and conditions include but are not limited to acne, athlete's foot, jock itch, ringworm, hemorrhoids, nail infections, skin infections, sunburn and sun- or injury-induced pigmentation, psoriasis, seborrhea, eczema and other dermatitises, dermatoses, and other diseases and pathological processes including kidney diseases, atherscleroses, etc. listed in Dorland's Illustrated Medical Dictionary, Stedman's Medical Dictionary, and other sources.
'The present compositions and methods are useful to minimize the appearance of skin imperfections, to help shed dry, damaged cells and unclog pores, to moisturize, exfoliate, and reveal younger-looking skin, to ameliorate and minimize the visible signs of aging, to ameliorate, minimize, and manage complexion problems, to gently peel away outer layers of dry, sun-damaged skin to expose younger looking skin, to leave skin smooth, soft, and refreshed, to ameliorate or minimize cosmetic problems associated with dry, sensitive, normal, combination-oily skin, to help control oily or problem-prone skin, to soothe the skin, improve skin texture, and restore moisture to the skin, to smooth fine lines in the skin, to even skin tones, to refine the texture of the skin, to improve and treat acne-prone skin, to protect against environmental skin aging, to lighten pigmented areas, and to enhance and accelerate the results achieved with other products.
Thus, the present composition may take the form of:
1. Makeup 2. Makeup Foundation 3. Makeup Remover 4. Eye Makeup 5. Eye Makeup Remover 6. Eye Makeup Pencil 7. Eye shadow 8. Facial Cream 9. Facial Cleanser 10. Facial Emulsion 11. Facial Mask 12. Facial Makeup S 13. Facial Scrub 14. Hand Cream 15. Body Cream 16. Sun Tan Lotion (including Sun Screen) 17. Lotion 18. Baby Oil 19. Baby Lotion 20. Anti-Aging Cream 21. Night Cream 22. Vanishing Cream 23. Cold Cream 24. Balm 25. Skin Conditioner 26. Disposable Wipe 27. Baby Wipe 28. Cleansing Cream 29. Lip Conditioner 30. Chap Preventative 31. Wound Care Ointment 32. Foundation for Lipstick (when applied to the lips before applying lipstick, the present composition locks or bonds the lipstick in place; no "feathering" or "bleeding" takes place and it looks as good 10 hours after application as it did just following application.) 33. Ingredient in Make-Up (lasts longer and goes on wet) 34. Anti-Perspirant/Deodorant 35. Wound Care (anti-adhesion, anti-infection, may contain antibiotic, e.g., Neosporin, ete.) 36. Surgical Site Wound Care 37. Implants (can provide anti-adhesion, anti-infection benefits when applied to the skin or tissues in contact with implants, e.g., pacemakers, etc. or on certain surfaces of the implant itself. Many conventional pacemaker implants produce infections which require removal and re-implantation. Application of the present composition to the skin or tissues in contact with the implant or on certain surfaces of the implant itself may prevent the adhesion of surrounding tissues to the implant, where desirable and also prevent or decrease the rate of infection, especially when the present composition comprises one or more anti-bacterial agents.
38. Indwelling Instruments (the present composition may provide anti-adhesion and anti-infection benefits when applied to the skin or tissues in contact with indwelling instruments, e.g., catheters, etc. or on certain surfaces of the indwelling instrument itself.) 39. Surgical Sites, Instruments, Sutures (coating surgical instruments andlor sutures with the present invention may provide anti-adhesion and anti-infection benefits and may reduce the resistance to placing the sutures by reducing the frictional resistance of the sutures.) 40. Athlete's Foot (the present invention even without an active agent may provide benefits; hexetidine is not only a preferred transfer agent but also a good anti-fungal material as well as a weak anti-bacterial material; thus, compositions which contain about 5% by weight hexetidine provide extended contact time with the affected area.) 41. Jock-Itch (jock-itch is caused by the same fungus responsible for athlete's foot and application of the present composition to the affected area may be effective for the prevention and/or treatment of jock-itch.) 42. Anti-Itch (the present compositions may be used as anti-itch compositions, even without inclusion of an active agent, especially when the itching is caused by external stimuli; traditional ani-itch agents, e.g., hydrocortizone may also be included in the present compositions.) 43. Diaper Rash (the present compositions may be applied to the affected area or to the diaper itself to combat diaper rash.) 44. Anti-Wrinkle Products (the present composition may be used to reduce wrinkles even without the presence of an active agent; alternatively, the present composition may contain an anti-wrinkle active agent such as shark liver oil.) _47_ 45. Anti-Anal Itch (the present composition may be applied to the affected area to combat anal itch even without an added active agent; traditional ani-itch agents, e.g., hydrocortizone may also be included in the present compositions;
the ability of the present compositions to adhere to moist surfaces means that it will stay in place longer and require fewer applications.) 46. Muscle Rub (compositions according to the present invention which contain a circulation-stimulating active agent, e.g., capsicum, etc. may be applied to the skin to treat sore or stiff muscles; the adherence of the present compositions to the skin means that the circulation-stimulating active agent (and resultant heat) will remain in contact with the affected area longer.) 47. Poison Oak, Ivy, Sumac, Etc. (the present compositions may be applied to the skin priox to engaging in activity which would bring the skin into contact with poisonous plants, e.g., poison ivy, poison oak, poison sumac, etc. and serve as a prophylactic barrier even without an active agent; the present compositions 1 S may also be applied to skin already suffering from poison ivy, poison oak, poison sumac, etc. to reduce the itching and spread of the condition with or without an anti-itching active agent.) 48. Depilatory Enhancer {hair absorbs moisture and is then more easily cut and/or removed; application of the present composition allows the depilatory to be applied when the hair is wet, thereby enhancing the cutting and/or removal of the hair.) 49. Anti-Drying (the present compositions may be used to form a protective barrier on the skin to prevent loss of moisture and/or oils from the skin.) 50. Other forms which will be apparent to those skilled in the art.
It should be understood that in the above-listed applications, the present composition may comprise either: (1) a transfer agent and a barrier material;
or (2) a transfer agent, barrier material, and active agent. In other words, for the applications listed above, good effects may be achieved even without the addition of an active agent, but in certain situations it may be advantageous and/or desirable to add an active agent.
The present compositions are typically applied to the skin in an amount effective to provide a protective barrier on the skin, usually about 80 micrograms to about 0.5 grams per cm2 of skin, preferably 100 micrograms to 0.1 grams per cm2 of skin.
Although the present invention has been described in detail in the context of skin care compositions and methods for treating the skin, the present compositions may be applied to substrates other than skin and may be used in methods other than I S skin care. In particular, it should be understood that the present compositions may be used in the following non-skin care applications.
Mold releases and casting adhesives. The release of a cast article from a mold may be enhanced by application of the present composition to the interior surface of the mold, or to the object to be cast or molded. This method may be especially effective for enhancing the release of a cast article made from a hydrophilic material {certain plastics and ceramics) from a mold which has a hydrophilic interior surface.
2. Ink and dye processing. The present compositions may be used to enhance the adherence of a hydrophobic ink to a hydrophilic substrate or vice-versa. In particular, the hydrophilic substrate may be coated with the present composition either aver the entire surface or in a patternwise fashion.
Application of the present composition to a hydrophilic surface may also be used to advantage in batik and tie-dye processes.
3. Anti-fouling applications. In marine applications, the present compositions may be applied to surfaces subject to fouling without hauling-out due to the ability of the present compositions to be applied to wet surfaces. The present compositions are useful as anti-fouling agents with or without active agents such as antibacterial agents. This is an important advantage, since most of the traditional anti-fouling materials, e.g., tin, copper, etc., are toxic to some marine organisms. When coated on a ship's hull, the present compositions may inhibit the attachment of marine growth to the hull or reduce the adherence of marine growth to the hull such that moving through the water at a speed of a few knots may be sufficient to remove any marine growth. In addition, the turbine blades of hydroelectric generators are plagued with fouling. Application of the present composition may be effective for reducing the fouling of turbine blades even in the face of the large shear forces encountered by turbine blades.
4. Leather treatments. Oils are destructive to leathers; they soften them and allow them to stretch and/or crack and they provide an attachment for grit and abrasives. Waxes are the preferred protectants. However, waxes applied -SO-directly to leathers are easily removed. Application of the present composition to leather provides extended benefits and reduced drying. In addition, since the outer layers slough off, less dirt will adhere to the leather.
5. Auto, vehicle protection. Application of the present composition to the interior and exterior surfaces of automobiles and other vehicles may be effective for protecting and/or enhancing the appearance and endurance or longevity of those surfaces. This may be especially effective for protecting hydrophilic surfaces such as certain seat coverings or other materials.
6. Wood protectant. W ood is negatively charged on the surface and contains moisture. The present compositions may thus be used as a furniture polish with excellent results, especially when rubbed down to a very thin but protective hydrophobic layer. The present compositions prevent water damage, e.g., water rings and stains. The present compositions may also be used to prevent wood from swelling, as in wood casement windows, and protect against mildew.
7. Metal treatments. The present compositions may be applied to metals to protect against oxidation, staining, chemical attack, and tarnishing.
8. Ceramic sealant. The present composition may be applied to certain ceramics to prevent and/or reduce the staining or fouling of the ceramic. For example, the present composition may be applied to showers, bathtubs, ceramic tile, and grout to prevent the formation of mold and mildew stains and bathtub rings.
9. Painted surfaces. The present composition may be applied to painted surfaces to afford a protective surface.
10. Floor wax. The present composition may be used as a floor wax, especially on floors with a hydrophilic surface, such as wood floors.
11. Anti-graffiti coatings. The present composition may be applied to surfaces which are subject to graffiti attacks, such as buildings, billboards, train cars, etc. The hydrophobic barrier afforded by the present composition not only makes it more difficult to apply the graffiti in the first place but also makes it easier to remove graffiti which is applied.
12. Paper and cardboard coatings. The present composition may be applied to paper or cardboard to obtain a moisture resistant barrier. This application may be useful not only for protecting the contents of a paper or cardboard package from water or moisture damage, but also for preparing a paper or cardboard package suitable for storing liquids such as milk or juice.
13. Plastics and fiberglass. The present composition may be applied to plastics or fiberglass to protect, lubricate, seal, or waterproof the plastic or fiberglass.
14. Anti-stick coatings. The present coatings may be applied to the cooking surfaces of cooking utensils, pots, pans, etc. as an anti-sticking agent. In such applications, it may be desirable to formulate the present composition with a volatile propellant and to apply the composition by means of an aerosol can.
15. Glass or china protectant. The present composition may be applied to glass or china to form a protective barrier which will keep the surface cleaner.
16. Pesticides. The present composition may be formulated with an active agent which is a pesticide and applied to any surface which is susceptible to infestation by pests. In a preferred embodiment, the present composition which contains the pesticide may be applied directly to the leaves or foliage of a plant.
17. Anti-fogging, anti-condensation agent. The present composition may be applied to surfaces which are susceptible to fogging, e.g., bathroom mirrors, windshields, eyeglasses, etc.
17. Anti-fogging, anti-condensation agent. The present composition may be applied to surfaces which are susceptible to fogging, e.g., bathroom mirrors, windshields, eyeglasses, etc.
18. Adhering lubricants to substrates. Application of the present composition to the surface of a substrate is useful far adhering a lubricant such as a wax, grease, petrolatum, teflon, or silicone to the surface of the substrate. In certain situations, it may be preferred or necessary to pretreat the surface of the substrate so that the present composition will itself adhere to the substrate.
The present compositions and methods provide a number of advantages which are not achieved by conventional compositions. In particular, the present compositions are characterized by the following advantages:
1. The present compositions are easily applied to a wet substrate. This advantage is particularly important in the context of skin care as in many circumstances it is desired to apply a skin composition to wet skin.
2. The present compositions bond well to the skin or other substrate resulting in a greater adhesion of the hydrophobic barrier.
3. The present compositions are resistant to removal. Mechanical action is often required to remove them from the skin or other substrate, since the barrier is not easily removed by solubility in aqueous, alcohol or other common personal care systems, but only by organic solvents such as hexane, etc., which are rarely encountered in skin care treatments or compositions.
4. The present compositions extend the time of contact with the skin or other substrate. This is an especially important benefit. Enhanced contact time means enhanced protection afforded by the protective hydrophobic barrier and longer contact time with any active agent present.
5. Enhanced activity of the active agent. The extended contact time exhibited by the present compositions may result in intensifying the benefits of any active agent present in the composition according to the present invention.
6. The present compositions provide a moisture barrier in both directions. In other words, the present compositions are able to keep moisture from escaping from the skin and are thus useful as moisturizers. In addition, the present compositions are also effective for keeping excessive moisture away from the skin and are thus useful for treating conditions related to contact of excess moisture with the skin, e.g., athlete's foot.
7. The present compositions are effective even without the addition of an active agent. In many cases, e.g., anti-perspirants, the combination of the transfer agent and the barrier material alone may provide the desired benefits even without the addition of an active agent. This is an important advantage. The barrier materials in many cases do not inhibit epidermal transpiration. Thus, the present compositions form a "breathable" protective coating. This coating may deny access to the skin or other substrate by bacteria, moisture, acids, and other toxic or contaminating substances.
Permeability/Poros~v/Discontinuitv:
The 'porosity', in the general or non-technical use of that word, or, more specifically, the permeability or continuity of the barriers formed by the compositions of the present invention, may be controlled by selection of viscosity modifiers, their S molecular weights and their concentrations in the formulations of the compositions of the present invention. In general, higher molecular weight materials increase cohesion between the molecules of the barrier materials and reduce the permeability or 'porosity' of the resulting composition when applied.
In addition, transfer agents vary in the extent to which they diffuse through the barrier material selected, so that some transfer agents, such as hexetidine, having a high mobility or diffusability in microcrystalline wax barriers, will demonstrate a high degree of permeability in the barriers formed by the compositions of the present invention and may carry with it other ingredients, such as certain of the active agents, providing permeability of the active agent both to the substrate and to the surfaces 1 S presented to the outer environment.
Characteristics of the substrate may also affect the observed permeability of the barriers formed by the compositions of the present invention in application.
Selecting very low molecular weight barrier materials may result in a very thin coating of as little as a single molecular layer of transfer agent combined with a single molecular layer of the barrier material with the functional continuity or porosity of the composition then more importantly dependent upon the characteristics of the substrate to which it is applied.
Specifically, it is possible to vary the permeability of the barrier to various substrates by varying the composition and/or concentrations of the barrier material, the transfer agent, viscosity modifiers, and active agents either independently or proportionately with respect to each other. In addition, the permeability of the barrier formed by the composition of the present invention will necessarily vary with respect to the specific permeant and with the environment in which it exists, e.g., the solubility of the transfer agent in the environment of the surfaces of the barrier formed by the composition of the present invention not in contact with the substrate.
S ac incl r a T i i is c T io Int a ' 1 T io In many applications, the surface energy (SE) of the barrier formed by the composition of the present invention will have important implications in functionality.
For example, during experimentation and testing of barriers formed by the compositions of the present invention on dental surfaces, it was found that S.
mutans, an important organism in oral care pathogenicity, will not attach to surfaces having an SE below a certain level. However when the SE is too low, the product can become aesthetically undesirable since the tongue cannot wet the surface of the barriers formed by the compositions of the present invention and the patient or user of the product is repeatedly frustrated in trying to do so. Thus a specific range of SEs is important in this application.
There are several factors which, independently and in combinations among them, may alter or affect the SE of the resulting barriers formed by the compositions of the present invention. Among them are:
1. Selection of the transfer agents) 2. Concentration of the transfer agents) 3. Solubility of the transfer agents) in the environment at the interface of the barrier formed by the composition of the present invention.
4. Selection of the barrier materials) 5. The rate of permeability/mobility/diffusability of the transfer agents) through the barrier formed by the composition of the present invention (for example as a function of the rate and extent to which the transfer agents) are replenished at the environmental interface as outer layers of the barrier formed by the composition of the present invention are removed); and that rate with respect to the rate of mobility of active agents through the materix of the barrier formed by the composition of the present invention, etc.
6. Characteristics of the environment, such as pH, etc.
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
EXAMPLES
In the following examples, and throughout this specification, all parts and percentages are by weight, and all temperatures are in degrees Celsius, unless expressly stated to be otherwise. Where the solids content of a dispersion or solution is reported, it expresses the weight of solids based on the total weight of the dispersion or solution, respectively. Where a molecular weight is specified, it is the molecular weight range ascribed to the product by the commercial supplier, which is identified.
Generally this is believed to be weight average molecular weight.
I. Methods.
A. The Wet Slide Test for Adherence:
The primary functional difference between the compositions of the present invention and compositions which contain barrier materials alone without a transfer agent is that the compositions of the present invention will adhere to a wet negatively-charged surface, such as a wet glass microscope slide but unmodified barrier materials will not adhere. Therefore, the primary functionality test for compositions of the present invention formulations is the Wet Slide Test, Protocol CB OI, which may be used both for initial evaluations of compositions of the present invention and for stability evaluations.
1. Materials a. Substrate Glass microscope slides, such as VWR Cat No 48312-400, approximate dimensions 1" x 3" x 1.0 mm, are cleaned (even if "pre-cleaned" slides are purchased) by manually washing for 30 seconds per slide in 2% aqueous sodium lauryl sulfate (90% or greater) solution or equivalent, exhaustively rinsing in tap water, followed by a final rinse in distilled or deionized water, and air drying at room temperature.
_~8_ b. Water Water for final rinse of substrate (above) and for test is Alhambra (brand) Distilled Drinking Water (McKesson Water Products Co., Pasadena, CA, 91107 U.S.A) or equivalent.
c. Ap liP cator Applicator is Longs (brand) Double-Tipped Cotton Swabs (Longs Drug Stores, Walnut Creek, CA 94596 U.S.A.) or equivalent.
d. Cg,~rol Hanson Microcrystalline Wax, Hansonwax code JH 835, Dilco Refining Division, Eastern Mohair and Trading Company, Inc. 73-35 Grand Avenue, Maspeth, New York 11378 U.S.A.
2. Procedure 1. The ambient temperature, the temperature of the water, the slide, and the test product must be 2515°C'..
2. Thoroughly coat the applicator tip with Control by rubbing the applicator on and in the Control product.
3. Holding the substrate (slide) horizontal, cover the upper surface of the substrate with water.
4. Wet the applicator and apply the Control to the water-covered surface of the substrate by rubbing the Control-coated tip of the applicator thereon.
5. If the Control transfers (visual assay) to the slide leaving a hydrophobic (high contact angle) area on the substrate, then the slide has been improperly cleaned (see Substrate, above). In such case, the whole batch of cleaned slides (Substrate) should be re-cleaned as provided under Methods (Substrate).
6. If the Control does not produce a hydrophobic area, then test a Test Product as in steps 1-4 (Procedure) above.
3. Evaluations Evaluation of performance is by a visual assay. First, observe a substrate which is covered with water. Note visually the magnitude of the contact angle between water and the surface (not an edge) of the substrate. Test materials which are judged to be effective (a report of +, ++, or +++) will produce a contact angle with water greater than that produced by water in contact with a cleaned substrate.
Test materials which are ineffective (a report of -) will not deposit material on the substrate in the test and will not produce an increased contact angle between water and treated surface.
4. Functionality - Describes the performance of Control or an ineffective test product.
No test material is deposited on the surface of the substrate (slide) in the test and the contact angle between water and the substrate is not changed as compared to the water-coated substrate prior to test.
+ Describes the performance of a marginally effective product. A small amount of test material is discontinuously deposited on the substrate (slide) in the test and the contact angle is little increased as compared to the water-coated substrate prior to test.
++ Describes a product of intermediate effectiveness. An intermediate amount of test material is deposited on the substrate (slide) in the test and the contact angle is somewhat increased as compared to the water-coated substrate prior to test.
+++ Describes a highly effective test material. A substantial amount of test material is continuously deposited on the substrate {slide) in the test and the contact angle is greatly increased as compared to the water-coated substrate prior to test.
II. Examples:
Examn_le 1.
Polydimethylsiloxanes (PMDS) of various molecular weights, obtained from United Chemical Technologies, Inc. {UCT), were mixed, using a spatula, with a transfer agent, hexetidine, in a ratio of 0.1 milliliter of transfer agent {abbreviated Hx) to 2.0 g of polymer or polymer mixture. Mixtures of polymers are in a ratio of 4 g of the higher MW polymer plus 1 g of the lower MW polymer. The higher molecular weight polymers required substantial time and force to produce a homogeneous mixture. Each of the mixtures described below was then tested in the wet slide test as indicated below:
Polydimethylsiloxanes:
Cat.No. Viscosity (csl MW Hazard P-034 0.65 162 Irritant P-040 50 3,780 None P-042 500 17,250 None P-044 5000 49,350 None P-048 100,000 139,000 None P-049 600,000 260,000 None P-049.5 1,000,000 308,000 None P-050 2,500,000 423,000 None Make the fo llowing formulations:
No. Composition W~~ Slide Test 1. P-034 -2. P-034, Hx ++
3. P-040 -4. P-040, Hx +++
5. P-042 -6. P-042, Hx +++
7. P-044 -8. P-044, Hx +++
9. P-048 -10. P-048, Hx +++
11. P-048, P-034, Hx +++
12. P-48, P-040, Hx +++
13. P-048, P-042, Hx +++
14. P-049 -15. P-049, Hx +++
16. P-049, P-034, Hx +++
17. P-049, P-040, Hx +++
18. P-049, P-042, Hx +++
The present compositions and methods provide a number of advantages which are not achieved by conventional compositions. In particular, the present compositions are characterized by the following advantages:
1. The present compositions are easily applied to a wet substrate. This advantage is particularly important in the context of skin care as in many circumstances it is desired to apply a skin composition to wet skin.
2. The present compositions bond well to the skin or other substrate resulting in a greater adhesion of the hydrophobic barrier.
3. The present compositions are resistant to removal. Mechanical action is often required to remove them from the skin or other substrate, since the barrier is not easily removed by solubility in aqueous, alcohol or other common personal care systems, but only by organic solvents such as hexane, etc., which are rarely encountered in skin care treatments or compositions.
4. The present compositions extend the time of contact with the skin or other substrate. This is an especially important benefit. Enhanced contact time means enhanced protection afforded by the protective hydrophobic barrier and longer contact time with any active agent present.
5. Enhanced activity of the active agent. The extended contact time exhibited by the present compositions may result in intensifying the benefits of any active agent present in the composition according to the present invention.
6. The present compositions provide a moisture barrier in both directions. In other words, the present compositions are able to keep moisture from escaping from the skin and are thus useful as moisturizers. In addition, the present compositions are also effective for keeping excessive moisture away from the skin and are thus useful for treating conditions related to contact of excess moisture with the skin, e.g., athlete's foot.
7. The present compositions are effective even without the addition of an active agent. In many cases, e.g., anti-perspirants, the combination of the transfer agent and the barrier material alone may provide the desired benefits even without the addition of an active agent. This is an important advantage. The barrier materials in many cases do not inhibit epidermal transpiration. Thus, the present compositions form a "breathable" protective coating. This coating may deny access to the skin or other substrate by bacteria, moisture, acids, and other toxic or contaminating substances.
Permeability/Poros~v/Discontinuitv:
The 'porosity', in the general or non-technical use of that word, or, more specifically, the permeability or continuity of the barriers formed by the compositions of the present invention, may be controlled by selection of viscosity modifiers, their S molecular weights and their concentrations in the formulations of the compositions of the present invention. In general, higher molecular weight materials increase cohesion between the molecules of the barrier materials and reduce the permeability or 'porosity' of the resulting composition when applied.
In addition, transfer agents vary in the extent to which they diffuse through the barrier material selected, so that some transfer agents, such as hexetidine, having a high mobility or diffusability in microcrystalline wax barriers, will demonstrate a high degree of permeability in the barriers formed by the compositions of the present invention and may carry with it other ingredients, such as certain of the active agents, providing permeability of the active agent both to the substrate and to the surfaces 1 S presented to the outer environment.
Characteristics of the substrate may also affect the observed permeability of the barriers formed by the compositions of the present invention in application.
Selecting very low molecular weight barrier materials may result in a very thin coating of as little as a single molecular layer of transfer agent combined with a single molecular layer of the barrier material with the functional continuity or porosity of the composition then more importantly dependent upon the characteristics of the substrate to which it is applied.
Specifically, it is possible to vary the permeability of the barrier to various substrates by varying the composition and/or concentrations of the barrier material, the transfer agent, viscosity modifiers, and active agents either independently or proportionately with respect to each other. In addition, the permeability of the barrier formed by the composition of the present invention will necessarily vary with respect to the specific permeant and with the environment in which it exists, e.g., the solubility of the transfer agent in the environment of the surfaces of the barrier formed by the composition of the present invention not in contact with the substrate.
S ac incl r a T i i is c T io Int a ' 1 T io In many applications, the surface energy (SE) of the barrier formed by the composition of the present invention will have important implications in functionality.
For example, during experimentation and testing of barriers formed by the compositions of the present invention on dental surfaces, it was found that S.
mutans, an important organism in oral care pathogenicity, will not attach to surfaces having an SE below a certain level. However when the SE is too low, the product can become aesthetically undesirable since the tongue cannot wet the surface of the barriers formed by the compositions of the present invention and the patient or user of the product is repeatedly frustrated in trying to do so. Thus a specific range of SEs is important in this application.
There are several factors which, independently and in combinations among them, may alter or affect the SE of the resulting barriers formed by the compositions of the present invention. Among them are:
1. Selection of the transfer agents) 2. Concentration of the transfer agents) 3. Solubility of the transfer agents) in the environment at the interface of the barrier formed by the composition of the present invention.
4. Selection of the barrier materials) 5. The rate of permeability/mobility/diffusability of the transfer agents) through the barrier formed by the composition of the present invention (for example as a function of the rate and extent to which the transfer agents) are replenished at the environmental interface as outer layers of the barrier formed by the composition of the present invention are removed); and that rate with respect to the rate of mobility of active agents through the materix of the barrier formed by the composition of the present invention, etc.
6. Characteristics of the environment, such as pH, etc.
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
EXAMPLES
In the following examples, and throughout this specification, all parts and percentages are by weight, and all temperatures are in degrees Celsius, unless expressly stated to be otherwise. Where the solids content of a dispersion or solution is reported, it expresses the weight of solids based on the total weight of the dispersion or solution, respectively. Where a molecular weight is specified, it is the molecular weight range ascribed to the product by the commercial supplier, which is identified.
Generally this is believed to be weight average molecular weight.
I. Methods.
A. The Wet Slide Test for Adherence:
The primary functional difference between the compositions of the present invention and compositions which contain barrier materials alone without a transfer agent is that the compositions of the present invention will adhere to a wet negatively-charged surface, such as a wet glass microscope slide but unmodified barrier materials will not adhere. Therefore, the primary functionality test for compositions of the present invention formulations is the Wet Slide Test, Protocol CB OI, which may be used both for initial evaluations of compositions of the present invention and for stability evaluations.
1. Materials a. Substrate Glass microscope slides, such as VWR Cat No 48312-400, approximate dimensions 1" x 3" x 1.0 mm, are cleaned (even if "pre-cleaned" slides are purchased) by manually washing for 30 seconds per slide in 2% aqueous sodium lauryl sulfate (90% or greater) solution or equivalent, exhaustively rinsing in tap water, followed by a final rinse in distilled or deionized water, and air drying at room temperature.
_~8_ b. Water Water for final rinse of substrate (above) and for test is Alhambra (brand) Distilled Drinking Water (McKesson Water Products Co., Pasadena, CA, 91107 U.S.A) or equivalent.
c. Ap liP cator Applicator is Longs (brand) Double-Tipped Cotton Swabs (Longs Drug Stores, Walnut Creek, CA 94596 U.S.A.) or equivalent.
d. Cg,~rol Hanson Microcrystalline Wax, Hansonwax code JH 835, Dilco Refining Division, Eastern Mohair and Trading Company, Inc. 73-35 Grand Avenue, Maspeth, New York 11378 U.S.A.
2. Procedure 1. The ambient temperature, the temperature of the water, the slide, and the test product must be 2515°C'..
2. Thoroughly coat the applicator tip with Control by rubbing the applicator on and in the Control product.
3. Holding the substrate (slide) horizontal, cover the upper surface of the substrate with water.
4. Wet the applicator and apply the Control to the water-covered surface of the substrate by rubbing the Control-coated tip of the applicator thereon.
5. If the Control transfers (visual assay) to the slide leaving a hydrophobic (high contact angle) area on the substrate, then the slide has been improperly cleaned (see Substrate, above). In such case, the whole batch of cleaned slides (Substrate) should be re-cleaned as provided under Methods (Substrate).
6. If the Control does not produce a hydrophobic area, then test a Test Product as in steps 1-4 (Procedure) above.
3. Evaluations Evaluation of performance is by a visual assay. First, observe a substrate which is covered with water. Note visually the magnitude of the contact angle between water and the surface (not an edge) of the substrate. Test materials which are judged to be effective (a report of +, ++, or +++) will produce a contact angle with water greater than that produced by water in contact with a cleaned substrate.
Test materials which are ineffective (a report of -) will not deposit material on the substrate in the test and will not produce an increased contact angle between water and treated surface.
4. Functionality - Describes the performance of Control or an ineffective test product.
No test material is deposited on the surface of the substrate (slide) in the test and the contact angle between water and the substrate is not changed as compared to the water-coated substrate prior to test.
+ Describes the performance of a marginally effective product. A small amount of test material is discontinuously deposited on the substrate (slide) in the test and the contact angle is little increased as compared to the water-coated substrate prior to test.
++ Describes a product of intermediate effectiveness. An intermediate amount of test material is deposited on the substrate (slide) in the test and the contact angle is somewhat increased as compared to the water-coated substrate prior to test.
+++ Describes a highly effective test material. A substantial amount of test material is continuously deposited on the substrate {slide) in the test and the contact angle is greatly increased as compared to the water-coated substrate prior to test.
II. Examples:
Examn_le 1.
Polydimethylsiloxanes (PMDS) of various molecular weights, obtained from United Chemical Technologies, Inc. {UCT), were mixed, using a spatula, with a transfer agent, hexetidine, in a ratio of 0.1 milliliter of transfer agent {abbreviated Hx) to 2.0 g of polymer or polymer mixture. Mixtures of polymers are in a ratio of 4 g of the higher MW polymer plus 1 g of the lower MW polymer. The higher molecular weight polymers required substantial time and force to produce a homogeneous mixture. Each of the mixtures described below was then tested in the wet slide test as indicated below:
Polydimethylsiloxanes:
Cat.No. Viscosity (csl MW Hazard P-034 0.65 162 Irritant P-040 50 3,780 None P-042 500 17,250 None P-044 5000 49,350 None P-048 100,000 139,000 None P-049 600,000 260,000 None P-049.5 1,000,000 308,000 None P-050 2,500,000 423,000 None Make the fo llowing formulations:
No. Composition W~~ Slide Test 1. P-034 -2. P-034, Hx ++
3. P-040 -4. P-040, Hx +++
5. P-042 -6. P-042, Hx +++
7. P-044 -8. P-044, Hx +++
9. P-048 -10. P-048, Hx +++
11. P-048, P-034, Hx +++
12. P-48, P-040, Hx +++
13. P-048, P-042, Hx +++
14. P-049 -15. P-049, Hx +++
16. P-049, P-034, Hx +++
17. P-049, P-040, Hx +++
18. P-049, P-042, Hx +++
19. P-049.5 -20. P-049.5, Hx +++
21. P-049.5, P-034, Hx +++
22. P-049.5, P-040, Hx +++
23. P-049.5, P-042, Hx +++
24. P-050 25. P-050, Hx +++
xam 100 Grams of UCT PSO50 polydimethylsiloxane, approximately 2,500,000 centistokes viscosity was mixed with 6.0 g of hexetidine. Clove oil (0.2 milliliter) was added for aroma and approximately 200 g of octamethylcyclotetrasiloxane (GE
1173) was added to decrease viscosity and allow thorough mixing. The formulation was tested as a protective hand and face preparation; users reported good effects. It was noted that the preparation could be applied to wet skin to moisturize and seal in moisture. Similar formulations having between half as much volatile silicone diluent to twice as much volatile silicone diluent had similar attributes but the more dilute formulations left a thinner coating of silicone on the skin.
x m 1 75 Grams of wax was melted at approximately 85 °C and 3.8 g of hexetidine was added. Then the mixture was diluted with approximately 150 g of SF 1173 (General Electric octamethylcyclotetrasiloxane). This formulation was tested as is in the wet slide test (results positive) and as a makeup foundation. It was also further diluted with up to 450 more grams of volatile silicone diluent. All dilutions gave similar results, some subjects preferring the less viscous formulations and some preferring the more viscous formulations. This formulation had exceptional performance in minimizing imperfections in the skin, especially when used as a make up foundation. In this mode of use, the skin is first washed thoroughly and Then the makeup foundation preparation is applied liberally to sparingly all over the face. It is notable that, even when applying the preparation to skin blemishes and lesions which are oozing tissue fluids, the preparation goes on easily and evenly, adhering uniformly to damaged and undamaged regions alike. After allowing a few moments for the foundation to dry, ordinary facial make up is applied in the usual manner. It is notable that when this formulation is applied to the skin as a foundation, ordinary makeup, which can often accentuate rather than hide oozing and dry skin blemishes and lesions, goes evenly and uniformly over healthy and blemished skin alike, evening out skin tones and hiding blemishes very effectively. It is also noted that when make up is removed by washing, this make up foundation preparation aids in cleaning the skin.
Example 4.
The following skin care formulations were prepared by mixing the ingredients under the conditions indicated:
formulation Wax Traps. Anent Diluent ~SF1202) Wet Slide Test 1 33g l.0ml 66g +++
2 49g l.Sml SOg +++
3 25g l.0ml 74g +++
4 30g l.0ml 63g +++
5 6.25g 0.25m1 43.5 +++
Numbers 1, 2, and 3 were prepared by melting the wax at approximately 85 °C, adding hexetidine and diluent, and mixing thoroughly. Number 5 is prepared by heating 25 g of number 3 to melt and diluting with 25 g of diluent, then cooling with stirring. Number 4 is a medicated formulation containing benzoyl peroxide, a recognized anti-acne agent. Benzoyl peroxide (BPO) is obtained from UCT as PC
020-KG, a paste which is 50% BPO in polydimethylsiloxane (PDMS). The BPO
paste is first mixed with diluent at approximately 25 °C then warmed to 75 °C in a water bath, while the wax is melted together with hexetidine at approximately 90 °C.
Then, the wax mixture is poured into the BPO-diluent mixture stirring on the water bath and the final mixture is cooled while shaking.
Formulations l, 2, 3, and 5 performed essentially the same as the formulation described in Example 3. Formulation 4 was cosmetically similar to the above formulations but was effective in one day and even more effective when used daily over two weeks in controlling acne. While BPO is a recognized anti-acne agent, most formulations incorporating this ingredient do not provide desirable cosmetic appearance when in use. Such conventional BPO formulations tend to dry and can often irritate the skin and often can accentuate rather than hide blemishes and tend to result in uneven skin tones, even when conventional make up is applied over a BPO
foundation. In contrast, formulation 4 exhibited all the favorable cosmetic attributes and functionalities of the other formulations ( 1, 2, 3, and 5 as well as Example 3) while treating and ameliorating acne lesions with superior efficacy. In short, the present formulation seems to enhance the activity of BPO, allowing it to work more quickly, to hide blemishes while it is working, and to allow BPO to be used for many days continuously for overall superior results.
Example S.
In this example, BPO is 50% Benzoyl Peroxide in PDMS, UCT # PC020-KG, Lot 12071 S. BPO is a monographed over-the counter (OTC) acne medicatian which, heretofore, has not been formulated in really esthetic products. This example, in which BPO constitutes 10% of the non-volatile fraction of the product (10% is the OTC limit), is prepared as follows:
Dilute 6.7 g of BPO in 68 g of cyclomethicone (GE SF 1202, decamethylcyclopentasiloxane and octamethylcyclotetrasiloxane) and warm to 80 °C
with stirring. Melt 25 g of wax and add 1.7 g of hexetidine. Pour the wax mixture into the BPO mixture and stir. Dispense into bottles.
A different order of addition (mix the BPO with the hexetidine, add melted wax, and then add the cyclomethicone) gave the same results.
The final composition is S% hexetidine, 10% BPO, in the wax (exclusive of volatiles), its performance was the same as for formulation number 4 in Example 4 above.
E~cample 6.
A waterproof sunscreen is prepared as follows:
Dissolve 1 S g of UTC PS OSO (2,500,000 cs PDMS) in 100 g of decamethylcyclotetrasiloxane. Add S g of 2-ethylhexyl-traps-methoxy-cinnamate ("Octamethyl Cinnamate," a UV absorber used in sunscreen products) and 1 g of hexetidine and stir. Observation: it doesn't wash off.
This Example is similar to Example 2 which uses PDMS as the barrier and Example 3 which uses wax as the barrier. This example uses a mixture of wax and 1 S PDMS as the barrier and is prepared using the following amounts of ingredients and the following procedure:
16.6 g of PS049.S (1,000,000 cs PDMS) 16.6 g of Wax 1 g of Hexetidene 66.4 g of solvent GE SF1202 Mix the PDMS with the solvent and warm to about 85 °C; add the wax and stir, to melt and mix; add the hexetidine and stir; and shake while cooling.
The formulation is superior to both Examples 2 and 3 in that the ratio of the two distinctly different barrier materials may be varied to produce cosmetic preparations which deliver a range of skin feel from relatively "hard," with a preponderance of wax, to supple, with a preponderance of PDMS.
Exa le Three formulations are prepared as follows:
A) 2% hexetidine.
Melt 83 grams of wax at 90 °C, add 1.5 grams of oil and 2 grams of hexetidine, and mix by stirring.
B) 6% Lecithin, 1 % Hexetidine.
Mix 6 grams of lecithin, 100 ml of hexane, and 15 grams of oil by stirnng, then add 1 gram of hexetidine with stirring. Warm just to the boiling point of hexane 1 S and gently evaporate the hexane. Add 78 grams of wax and melt at 75 ° C on a water bath. Mix by stirring.
C) 12% Lecithin Mix 12 grams of of lecithin, 100 ml of hexane, and 15 grams of oil by stirring. Warm just to the boiling point of hexane and gently evaporate the hexane.
Add 73 grams of wax and melt at 75 °C on a water bath. Mix by stirring.
Melt A and C on a water bath. Add 50 grams of A to 50 grams of B, and mix by stirring.
Formula Barrier Transfer ViscosityRating W Agent ( Modifier ax) Lecithin Hexetidine(oil) A 83g Og 2g 15g +++
B 78g 6g lg 15g +++
C 73g 12g Og 15g +++
+++ Highly effective, ++ Effective, + Somewhat Effective, - Ineffective.
The lecithin formulations give an exceptional degree of suppleness, and the lecithin itself may, to some extent, plasticize the skin, this being a natural component of the skin.
Exam l A silicone-based skin formulation is prepared using the following amounts of ingredients and the following procedure:
33.0 g of PS 050 (2,500,000 cs PDMS), 132 g of GE (~ctamethylcyclotetrasiloxane, and 1.0 ml of hexetidine, Heat no higher than 60°C and stir overnight.
This composition passes the wet slide test.
Exam 1~ a 10.
These silicone formulations are prepared using the following amounts of ingredients and the following procedures:
1. Mix 23.7 g of UCT PS 050 (2,500,000cs PDMS) with 71.1 g of Decamethycyclopentasiloxane (G.E.);
Heat and stir to dissolve (Takes a lone time);
Add 1.0 g of hexetidine; and mix well.
Wet glass slide test: +++
2. Melt 40.5 g of Wax, at ca. 85 °C;
Add 4.0 g of Hexetidine, mix well;
Add 40.5 g of Decamethycyclopentasiloxane (G.E.); and Mix well.
Wet glass slide test: +++
3. Mix 33.2 g of melted formulation no. 2 with 33.2 g of Decamethylcyciopentasiloxane (G.E.);
Mix well.
Wet glass slide test: +++
4. Controls Wet glass slide test:
Wax:
Decamethycyclopentasiloxane (G.E.) -UCT PS OSO (2,500,000cs PDMS) -Note that a control formulation, without transfer agent, did not pass the wet slide test.
_70_ Ex~ In a 11.
An athletes foot formulation is prepared using the following amounts of ingredients and the following procedure;
278 g of wax (75%), 55 g of oil (15%), and 37 g of hexetidine (10%) (50 ml of 90% hexetidine).
Heat to melt wax and mix; and Dispense into containers.
It is reported that this formulation rapidly treats and cures athletes foot (fungal infection).
Wax-Based Cream Formulation:
The wax-based hand-cream formulation was prepared by combining 10 grams of microcrystalline wax, 10 grams of 50% lecithin* dissolved in paraffin oil, 10 grams of water, 2 grams of isopropyl alcohol, 0.5 grams of hexetidine and 1 gram of citronella fragrance (Aura Cacia,** 100% essential oil). The mixture was liquefied by heating to approx. 90°C. It was stirred vigorously until the temperature dropped below 50°C and the mixture solidified into a formulation which is smooth and creamy in consistency. In this type of formulation, the ratio of water and wax may be varied to produce cosmetic preparations which deliver a range of skin feel from relatively "soft," with a preponderance of water, to 'hard," with a preponderance of wax.
Example 13.
The wax-based cream composition, suitable as a base for makeup, was prepared by combining 10 grams of microcrystalline wax with 4 grams of 50%
lecithin dissolved in paraffin oil, 2 grams of 50% beeswax dissolved in paraffin oil, 10 grams of water, 0.5 grams of hexetidine, and 1 gram of orange fragrance (Aura Cacia, 100% essential oil). The mixture was liquefied by heating to approx.
90°C. It was stirred vigorously until the temperature. dropped below 50°C and the mixture solidified into a smooth creamy consistency suitable for mascaras and eye makeup.
Wax 25% to 80%
Lecithin 1 % to 50%
Water 25% to 50%
* Manufactured by Archer Daniel Midload Co. under trade name of ULTRALEC P, lot# UF/040 * * Manufactured by Aura C:acia, Weaverville, Ca.
Chitosan-Cont 'fining Com~~ition:
Exam lp a 14.
A composition including de-oiled lecithin is shown in the table below:
WO 00/3$617 PCTNS99/30003 Components Weight Microcrystalline 70 Wax Paraffine Oil 25 Liquid Lecithin 5 In a typical product preparation, 10 grams of the above formulation is liquefied by heating to 80-100°C and combined with 10 grams of de-acetylated chitosan (Aldrich Chemical Co., 1001 West St. Paul Ave., Milwaukee, WI 53233, catalog no. 44,887-7). The components are mixed until a homogenous paste is obtained. In a separate container, 100 ml of water containing one g of a chitosan fiber dispersion is heated to 80°C and maintained at this temperature. The lecithin/chitosan paste is then introduced into the warm water and mixed strongly until the paste transforms into small granules with a typical size of 1 to 2 millimeters. The granules are filtered and dried in air to yield a free-flowing and non-sticky product.
The product then can be added to a skin care formulation in sufficient quantity ( 1 to 90 wt.%, preferably 5 to 75 wt.%, more preferably 10 to 50 wt.%) to assure transfer of the formulation onto the animal's skin. In modification to this approach, the lecithin/chitosan paste can be extruded into cold water resulting in the formation of rods or pellets of any desired size and dimensions.
WO 00/38617 PC'I"/US99/30003 Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
All patents and other references mentioned above are incorporated in full herein by this reference, the same as if set forth at length.
xam 100 Grams of UCT PSO50 polydimethylsiloxane, approximately 2,500,000 centistokes viscosity was mixed with 6.0 g of hexetidine. Clove oil (0.2 milliliter) was added for aroma and approximately 200 g of octamethylcyclotetrasiloxane (GE
1173) was added to decrease viscosity and allow thorough mixing. The formulation was tested as a protective hand and face preparation; users reported good effects. It was noted that the preparation could be applied to wet skin to moisturize and seal in moisture. Similar formulations having between half as much volatile silicone diluent to twice as much volatile silicone diluent had similar attributes but the more dilute formulations left a thinner coating of silicone on the skin.
x m 1 75 Grams of wax was melted at approximately 85 °C and 3.8 g of hexetidine was added. Then the mixture was diluted with approximately 150 g of SF 1173 (General Electric octamethylcyclotetrasiloxane). This formulation was tested as is in the wet slide test (results positive) and as a makeup foundation. It was also further diluted with up to 450 more grams of volatile silicone diluent. All dilutions gave similar results, some subjects preferring the less viscous formulations and some preferring the more viscous formulations. This formulation had exceptional performance in minimizing imperfections in the skin, especially when used as a make up foundation. In this mode of use, the skin is first washed thoroughly and Then the makeup foundation preparation is applied liberally to sparingly all over the face. It is notable that, even when applying the preparation to skin blemishes and lesions which are oozing tissue fluids, the preparation goes on easily and evenly, adhering uniformly to damaged and undamaged regions alike. After allowing a few moments for the foundation to dry, ordinary facial make up is applied in the usual manner. It is notable that when this formulation is applied to the skin as a foundation, ordinary makeup, which can often accentuate rather than hide oozing and dry skin blemishes and lesions, goes evenly and uniformly over healthy and blemished skin alike, evening out skin tones and hiding blemishes very effectively. It is also noted that when make up is removed by washing, this make up foundation preparation aids in cleaning the skin.
Example 4.
The following skin care formulations were prepared by mixing the ingredients under the conditions indicated:
formulation Wax Traps. Anent Diluent ~SF1202) Wet Slide Test 1 33g l.0ml 66g +++
2 49g l.Sml SOg +++
3 25g l.0ml 74g +++
4 30g l.0ml 63g +++
5 6.25g 0.25m1 43.5 +++
Numbers 1, 2, and 3 were prepared by melting the wax at approximately 85 °C, adding hexetidine and diluent, and mixing thoroughly. Number 5 is prepared by heating 25 g of number 3 to melt and diluting with 25 g of diluent, then cooling with stirring. Number 4 is a medicated formulation containing benzoyl peroxide, a recognized anti-acne agent. Benzoyl peroxide (BPO) is obtained from UCT as PC
020-KG, a paste which is 50% BPO in polydimethylsiloxane (PDMS). The BPO
paste is first mixed with diluent at approximately 25 °C then warmed to 75 °C in a water bath, while the wax is melted together with hexetidine at approximately 90 °C.
Then, the wax mixture is poured into the BPO-diluent mixture stirring on the water bath and the final mixture is cooled while shaking.
Formulations l, 2, 3, and 5 performed essentially the same as the formulation described in Example 3. Formulation 4 was cosmetically similar to the above formulations but was effective in one day and even more effective when used daily over two weeks in controlling acne. While BPO is a recognized anti-acne agent, most formulations incorporating this ingredient do not provide desirable cosmetic appearance when in use. Such conventional BPO formulations tend to dry and can often irritate the skin and often can accentuate rather than hide blemishes and tend to result in uneven skin tones, even when conventional make up is applied over a BPO
foundation. In contrast, formulation 4 exhibited all the favorable cosmetic attributes and functionalities of the other formulations ( 1, 2, 3, and 5 as well as Example 3) while treating and ameliorating acne lesions with superior efficacy. In short, the present formulation seems to enhance the activity of BPO, allowing it to work more quickly, to hide blemishes while it is working, and to allow BPO to be used for many days continuously for overall superior results.
Example S.
In this example, BPO is 50% Benzoyl Peroxide in PDMS, UCT # PC020-KG, Lot 12071 S. BPO is a monographed over-the counter (OTC) acne medicatian which, heretofore, has not been formulated in really esthetic products. This example, in which BPO constitutes 10% of the non-volatile fraction of the product (10% is the OTC limit), is prepared as follows:
Dilute 6.7 g of BPO in 68 g of cyclomethicone (GE SF 1202, decamethylcyclopentasiloxane and octamethylcyclotetrasiloxane) and warm to 80 °C
with stirring. Melt 25 g of wax and add 1.7 g of hexetidine. Pour the wax mixture into the BPO mixture and stir. Dispense into bottles.
A different order of addition (mix the BPO with the hexetidine, add melted wax, and then add the cyclomethicone) gave the same results.
The final composition is S% hexetidine, 10% BPO, in the wax (exclusive of volatiles), its performance was the same as for formulation number 4 in Example 4 above.
E~cample 6.
A waterproof sunscreen is prepared as follows:
Dissolve 1 S g of UTC PS OSO (2,500,000 cs PDMS) in 100 g of decamethylcyclotetrasiloxane. Add S g of 2-ethylhexyl-traps-methoxy-cinnamate ("Octamethyl Cinnamate," a UV absorber used in sunscreen products) and 1 g of hexetidine and stir. Observation: it doesn't wash off.
This Example is similar to Example 2 which uses PDMS as the barrier and Example 3 which uses wax as the barrier. This example uses a mixture of wax and 1 S PDMS as the barrier and is prepared using the following amounts of ingredients and the following procedure:
16.6 g of PS049.S (1,000,000 cs PDMS) 16.6 g of Wax 1 g of Hexetidene 66.4 g of solvent GE SF1202 Mix the PDMS with the solvent and warm to about 85 °C; add the wax and stir, to melt and mix; add the hexetidine and stir; and shake while cooling.
The formulation is superior to both Examples 2 and 3 in that the ratio of the two distinctly different barrier materials may be varied to produce cosmetic preparations which deliver a range of skin feel from relatively "hard," with a preponderance of wax, to supple, with a preponderance of PDMS.
Exa le Three formulations are prepared as follows:
A) 2% hexetidine.
Melt 83 grams of wax at 90 °C, add 1.5 grams of oil and 2 grams of hexetidine, and mix by stirring.
B) 6% Lecithin, 1 % Hexetidine.
Mix 6 grams of lecithin, 100 ml of hexane, and 15 grams of oil by stirnng, then add 1 gram of hexetidine with stirring. Warm just to the boiling point of hexane 1 S and gently evaporate the hexane. Add 78 grams of wax and melt at 75 ° C on a water bath. Mix by stirring.
C) 12% Lecithin Mix 12 grams of of lecithin, 100 ml of hexane, and 15 grams of oil by stirring. Warm just to the boiling point of hexane and gently evaporate the hexane.
Add 73 grams of wax and melt at 75 °C on a water bath. Mix by stirring.
Melt A and C on a water bath. Add 50 grams of A to 50 grams of B, and mix by stirring.
Formula Barrier Transfer ViscosityRating W Agent ( Modifier ax) Lecithin Hexetidine(oil) A 83g Og 2g 15g +++
B 78g 6g lg 15g +++
C 73g 12g Og 15g +++
+++ Highly effective, ++ Effective, + Somewhat Effective, - Ineffective.
The lecithin formulations give an exceptional degree of suppleness, and the lecithin itself may, to some extent, plasticize the skin, this being a natural component of the skin.
Exam l A silicone-based skin formulation is prepared using the following amounts of ingredients and the following procedure:
33.0 g of PS 050 (2,500,000 cs PDMS), 132 g of GE (~ctamethylcyclotetrasiloxane, and 1.0 ml of hexetidine, Heat no higher than 60°C and stir overnight.
This composition passes the wet slide test.
Exam 1~ a 10.
These silicone formulations are prepared using the following amounts of ingredients and the following procedures:
1. Mix 23.7 g of UCT PS 050 (2,500,000cs PDMS) with 71.1 g of Decamethycyclopentasiloxane (G.E.);
Heat and stir to dissolve (Takes a lone time);
Add 1.0 g of hexetidine; and mix well.
Wet glass slide test: +++
2. Melt 40.5 g of Wax, at ca. 85 °C;
Add 4.0 g of Hexetidine, mix well;
Add 40.5 g of Decamethycyclopentasiloxane (G.E.); and Mix well.
Wet glass slide test: +++
3. Mix 33.2 g of melted formulation no. 2 with 33.2 g of Decamethylcyciopentasiloxane (G.E.);
Mix well.
Wet glass slide test: +++
4. Controls Wet glass slide test:
Wax:
Decamethycyclopentasiloxane (G.E.) -UCT PS OSO (2,500,000cs PDMS) -Note that a control formulation, without transfer agent, did not pass the wet slide test.
_70_ Ex~ In a 11.
An athletes foot formulation is prepared using the following amounts of ingredients and the following procedure;
278 g of wax (75%), 55 g of oil (15%), and 37 g of hexetidine (10%) (50 ml of 90% hexetidine).
Heat to melt wax and mix; and Dispense into containers.
It is reported that this formulation rapidly treats and cures athletes foot (fungal infection).
Wax-Based Cream Formulation:
The wax-based hand-cream formulation was prepared by combining 10 grams of microcrystalline wax, 10 grams of 50% lecithin* dissolved in paraffin oil, 10 grams of water, 2 grams of isopropyl alcohol, 0.5 grams of hexetidine and 1 gram of citronella fragrance (Aura Cacia,** 100% essential oil). The mixture was liquefied by heating to approx. 90°C. It was stirred vigorously until the temperature dropped below 50°C and the mixture solidified into a formulation which is smooth and creamy in consistency. In this type of formulation, the ratio of water and wax may be varied to produce cosmetic preparations which deliver a range of skin feel from relatively "soft," with a preponderance of water, to 'hard," with a preponderance of wax.
Example 13.
The wax-based cream composition, suitable as a base for makeup, was prepared by combining 10 grams of microcrystalline wax with 4 grams of 50%
lecithin dissolved in paraffin oil, 2 grams of 50% beeswax dissolved in paraffin oil, 10 grams of water, 0.5 grams of hexetidine, and 1 gram of orange fragrance (Aura Cacia, 100% essential oil). The mixture was liquefied by heating to approx.
90°C. It was stirred vigorously until the temperature. dropped below 50°C and the mixture solidified into a smooth creamy consistency suitable for mascaras and eye makeup.
Wax 25% to 80%
Lecithin 1 % to 50%
Water 25% to 50%
* Manufactured by Archer Daniel Midload Co. under trade name of ULTRALEC P, lot# UF/040 * * Manufactured by Aura C:acia, Weaverville, Ca.
Chitosan-Cont 'fining Com~~ition:
Exam lp a 14.
A composition including de-oiled lecithin is shown in the table below:
WO 00/3$617 PCTNS99/30003 Components Weight Microcrystalline 70 Wax Paraffine Oil 25 Liquid Lecithin 5 In a typical product preparation, 10 grams of the above formulation is liquefied by heating to 80-100°C and combined with 10 grams of de-acetylated chitosan (Aldrich Chemical Co., 1001 West St. Paul Ave., Milwaukee, WI 53233, catalog no. 44,887-7). The components are mixed until a homogenous paste is obtained. In a separate container, 100 ml of water containing one g of a chitosan fiber dispersion is heated to 80°C and maintained at this temperature. The lecithin/chitosan paste is then introduced into the warm water and mixed strongly until the paste transforms into small granules with a typical size of 1 to 2 millimeters. The granules are filtered and dried in air to yield a free-flowing and non-sticky product.
The product then can be added to a skin care formulation in sufficient quantity ( 1 to 90 wt.%, preferably 5 to 75 wt.%, more preferably 10 to 50 wt.%) to assure transfer of the formulation onto the animal's skin. In modification to this approach, the lecithin/chitosan paste can be extruded into cold water resulting in the formation of rods or pellets of any desired size and dimensions.
WO 00/38617 PC'I"/US99/30003 Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
All patents and other references mentioned above are incorporated in full herein by this reference, the same as if set forth at length.
Claims (23)
LETTERS PATENT OF THE UNITED STATES IS:
1. A composition comprising (a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 75 to 99.75 wt.%, based on-the total weight of (a) and (b), of one or more barrier materials.
2. A composition, comprising:
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b') 0.25 to 99.99 wt.%, based on the total weight of (b') and (b'''), of one or more transfer agents; and (b''') 0.01 to 99.75 wt.%, based on the total weight of (b') and (b'''), of at least one skin care active agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b') 0.25 to 99.99 wt.%, based on the total weight of (b') and (b'''), of one or more transfer agents; and (b''') 0.01 to 99.75 wt.%, based on the total weight of (b') and (b'''), of at least one skin care active agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
3. The composition of Claim 2, wherein said skin care active agent is selected from the group consisting of Acetic Acid Aclometasone Dipropionate Acyclovir Alclometasone Dipropionate Aluminum Chlorhydrate Aluminum Chlorhydroxide Aluminum Chloride Hexahydrate Amcinonide Aminobenzoate Potassium Ammonium Lactate Ammonium Mercury Amphotericin B
Anthralin Antimicrobial Agents Bacitracin Balsam Peru Benzocaine Benzoin Compoundecylenate Benzoyl Peroxide (BPO) Beta-Carotene Betamethasone Acetate Betamethasone Dipropionate Betamethasone Sodium Phosphate Betamethasone Valerate Butaconazole Nitrate Butamben Picrate Canthardin Carbol Fuchsin Castor Oil Cetylpyridinium Chloride Chloramphenicol Chlorcyclizine Chlorhexidine Chlorhexidine Acetate Chlorhexidine Gluconate Chloroxine Chloroxynol Ciclopirox Olamine Clindamycin HCl Clioquinol Clobetasol Propionate Clocortolone Pivalate Clotrimazole Coal Tar Collagenase Cortisone Cortisone Acetate Crotamiton Cyclopentolate HCl Dapsone Desonide Desoxymetasone Desoxyribonuclease Dexamethasone Dexamethasone Acetate Dexamethasone Sodium Phosphate Dibucaine Dichloroacetic Acid Dichlorophene Diflorasone Diacetate Diperodon Econazole Nitrate Ephedrine HCl Erythromycin Estradiol Etretinate Fibrinolysin Flucinolone Flucinolone Acetonide Fluocinonide Fluorouracil Fluradrenolone Flurandrenolide Fluticasone Propionate Formaldehyde Gentamycin Sulfate Gramicid Griseofulvin Guaifenesin Halcinonide Halobetasol Propionate Haloprogin Hexachlorophene Hexetadine Hyaluronidase Hydrocodone Hydrocortisone Hydrocortisone Acetate Hydrocortisone Butyrate Hydrocortisone Sodium Phosphate Hydrocortisone Sodium Succinate Hydrocortisone Valerate Hydroquinone Hydroxyzine HCl Hydroxyzine Pamoate Iodine Iodochlorhydrocodone Iodoquinol Isotretinoin Ketoconazole Lactic Acid Lecithin Lidocaine Hydrochloride Lindane Mafenide Acetate Meclocycline Sulfosalicylate Methoxsalen Methylprednisone Methylprednisone Acetate Methylprednisone Sodium Succinate Metronidazole Miconazole Nitrate Minoxidil Mometasone Furoate Monobenzone Mupriocin Naftifine HCl Neomycin Sulfate Nitrofurazone Nystatin Octyl Methoxycinnamate Oxybenzone Oxyquinoline Sulfate Papain para-Aminobenzoic Acid Permethrin Phentermine HCl Podophylum Polymyxin B Sulfate Potassium Iodide Pramoxine HCl Prednicarbate Prednisolone Sodium Phosphate Prednisone Pseudoephedrine Pyrogallic Acid Retinoic Acid Retinol Salicylic Acid Saluminum Acid Scarlet Red Selenium Sulfide Silver Nitrate Silver Sulfadiazine Sodium Sulfacetimide Sodium Thiosulfate Streptokinase Sulconazole Sulconazole Nitrate Sulfabenzamide Sulfacetamide Sulfanilamide Sulfathiazole Sulfur Sunscreen Agents Sutilains Terconazole Tetracaine Tetracycline Tretinoin Triacetin Triamcinolone Triamcinolone Acetonide Triamcinolone Diacetate Trimeprazine Tartrate Trioxsalen Triple Dye Trypsin Undecylenic Acid Urea Vitamins (all) Zinc Oxide Zinc Undecylenate and other agents known in the art to have medical, cosmetic, or other effects on the skin.
Anthralin Antimicrobial Agents Bacitracin Balsam Peru Benzocaine Benzoin Compoundecylenate Benzoyl Peroxide (BPO) Beta-Carotene Betamethasone Acetate Betamethasone Dipropionate Betamethasone Sodium Phosphate Betamethasone Valerate Butaconazole Nitrate Butamben Picrate Canthardin Carbol Fuchsin Castor Oil Cetylpyridinium Chloride Chloramphenicol Chlorcyclizine Chlorhexidine Chlorhexidine Acetate Chlorhexidine Gluconate Chloroxine Chloroxynol Ciclopirox Olamine Clindamycin HCl Clioquinol Clobetasol Propionate Clocortolone Pivalate Clotrimazole Coal Tar Collagenase Cortisone Cortisone Acetate Crotamiton Cyclopentolate HCl Dapsone Desonide Desoxymetasone Desoxyribonuclease Dexamethasone Dexamethasone Acetate Dexamethasone Sodium Phosphate Dibucaine Dichloroacetic Acid Dichlorophene Diflorasone Diacetate Diperodon Econazole Nitrate Ephedrine HCl Erythromycin Estradiol Etretinate Fibrinolysin Flucinolone Flucinolone Acetonide Fluocinonide Fluorouracil Fluradrenolone Flurandrenolide Fluticasone Propionate Formaldehyde Gentamycin Sulfate Gramicid Griseofulvin Guaifenesin Halcinonide Halobetasol Propionate Haloprogin Hexachlorophene Hexetadine Hyaluronidase Hydrocodone Hydrocortisone Hydrocortisone Acetate Hydrocortisone Butyrate Hydrocortisone Sodium Phosphate Hydrocortisone Sodium Succinate Hydrocortisone Valerate Hydroquinone Hydroxyzine HCl Hydroxyzine Pamoate Iodine Iodochlorhydrocodone Iodoquinol Isotretinoin Ketoconazole Lactic Acid Lecithin Lidocaine Hydrochloride Lindane Mafenide Acetate Meclocycline Sulfosalicylate Methoxsalen Methylprednisone Methylprednisone Acetate Methylprednisone Sodium Succinate Metronidazole Miconazole Nitrate Minoxidil Mometasone Furoate Monobenzone Mupriocin Naftifine HCl Neomycin Sulfate Nitrofurazone Nystatin Octyl Methoxycinnamate Oxybenzone Oxyquinoline Sulfate Papain para-Aminobenzoic Acid Permethrin Phentermine HCl Podophylum Polymyxin B Sulfate Potassium Iodide Pramoxine HCl Prednicarbate Prednisolone Sodium Phosphate Prednisone Pseudoephedrine Pyrogallic Acid Retinoic Acid Retinol Salicylic Acid Saluminum Acid Scarlet Red Selenium Sulfide Silver Nitrate Silver Sulfadiazine Sodium Sulfacetimide Sodium Thiosulfate Streptokinase Sulconazole Sulconazole Nitrate Sulfabenzamide Sulfacetamide Sulfanilamide Sulfathiazole Sulfur Sunscreen Agents Sutilains Terconazole Tetracaine Tetracycline Tretinoin Triacetin Triamcinolone Triamcinolone Acetonide Triamcinolone Diacetate Trimeprazine Tartrate Trioxsalen Triple Dye Trypsin Undecylenic Acid Urea Vitamins (all) Zinc Oxide Zinc Undecylenate and other agents known in the art to have medical, cosmetic, or other effects on the skin.
4. A method for forming a protective barrier on skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of transfer agent;
and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of a barrier material.
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of transfer agent;
and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of a barrier material.
5. A method for cleaning and removing contaminants from the skin while forming a protective barrier on skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of a transfer agent; and (b) 75 to 99.75 wt%, based on the total weight of (a) and (b), of a barrier material.
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of a transfer agent; and (b) 75 to 99.75 wt%, based on the total weight of (a) and (b), of a barrier material.
6. A method for applying a skin care agent to skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'') 0.25 to 99.99 wt.%, based on the total weight of (b'') and (b'''), of one or more transfer agents; and (b''') 0.01 to 99.75 wt.%, based on the total weight of (b'') and (b'''), of at least one skin care agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'') 0.25 to 99.99 wt.%, based on the total weight of (b'') and (b'''), of one or more transfer agents; and (b''') 0.01 to 99.75 wt.%, based on the total weight of (b'') and (b'''), of at least one skin care agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
7. A method for cleaning and removing contaminants from the skin while applying a skin care agent to skin, said method comprising applying an effective amount of composition to skin, said composition comprising:
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'') 0.25 to 99.99 wt.%, based on the total weight of (b'') and (b'''), of one or more transfer agents; and (b''') 0.01 to 99.75 wt.%, based on the total weight of (b'') and (b'''), of at least one skin care agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'') 0.25 to 99.99 wt.%, based on the total weight of (b'') and (b'''), of one or more transfer agents; and (b''') 0.01 to 99.75 wt.%, based on the total weight of (b'') and (b'''), of at least one skin care agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
8. A composition which comprises:
(1) 25 to 80 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water.
(1) 25 to 80 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water.
9. The composition of claim 8, which comprises:
(1) 30 to 60 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 10 to 40 wt.%, based on the total weight of (1), (2), and (3), of lecithin; and (3) 30 to 40 wt.%, based on the total weight of (1), (2), and (3), of water.
(1) 30 to 60 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 10 to 40 wt.%, based on the total weight of (1), (2), and (3), of lecithin; and (3) 30 to 40 wt.%, based on the total weight of (1), (2), and (3), of water.
10. A method for forming a protective barrier on skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(1) 25 to 80 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water.
(1) 25 to 80 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water.
11. A method for cleaning and removing contaminants from the skin while performing a protective barrier on skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(1) 25 to 80 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water.
(1) 25 to 80 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 1 to 50 wt.%, based on the total weight of (1), (2), and (3), of lecithin;
and (3) 20 to 50 wt.%, based on the total weight of (1), (2), and (3), of water.
12. The method of Claim 10 or 11, wherein said composition comprises:
(1) 30 to b0 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 10 to 40 wt.%, based on the total weight of (1), (2), and (3), of lecithin; and (3) 30 to 40 wt.%, based on the total weight of (1), (2), and (3), of water.
(1) 30 to b0 wt.%, based on the total weight of (1), (2), and (3), of a barrier material;
(2) 10 to 40 wt.%, based on the total weight of (1), (2), and (3), of lecithin; and (3) 30 to 40 wt.%, based on the total weight of (1), (2), and (3), of water.
13. A composition which comprises:
(i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 1 to 50 wt.%, based on the total weight of (i), (ii), and (iii}, of chitosan.
(i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 1 to 50 wt.%, based on the total weight of (i), (ii), and (iii}, of chitosan.
14. The composition of Claim 13, which comprises:
(i) 5 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 15 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 10 to 40 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
(i) 5 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 15 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 10 to 40 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
15. A method for forming a protective barrier on skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 1 to 50 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
(i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 1 to 50 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
16. A method for cleaning and removing contaminants from the skin while forming a protective barrier on skin, said method comprising applying an effective amount of a composition to skin, said composition comprising:
(i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 1 to 50 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
(i) 1 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 10 to 30 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 1 to 50 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
17. The method of Claim 15 or 16, wherein said composition comprises:
(i) 5 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 15 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 10 to 40 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
(i) 5 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of lecithin;
(ii) 15 to 25 wt.%, based on the total weight of (i), (ii), and (iii), of a barrier material; and (iii) 10 to 40 wt.%, based on the total weight of (i), (ii), and (iii), of chitosan.
18. A method for forming a hydrophobic barrier on a surface, comprising applying to said surface an effective amount of a composition comprising:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of one or more barrier materials.
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of one or more barrier materials.
19. A method for cleaning and removing contaminants from a surface while forming a hydrophobic barrier on a surface, comprising applying to said surface an effective amount of a composition comprising:
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of one or more barrier materials.
(a) 0.25 to 25 wt.%, based on the total weight of (a) and (b), of one or more transfer agents; and (b) 75 to 99.75 wt.%, based on the total weight of (a) and (b), of one or more barrier materials.
20. The method of Claim 18 or 19, wherein said surface is selected from the group consisting of molds, ship hulls, leather, automobile surfaces, wood, metal, painted surfaces, floors, walls, billboards, train cars, paper, cardboard, pots, pans, cooking utensils, glass, china, plant foliage, polymers, plastics, fiberglass, fabrics, resins, composites including carbon fiber and graphitic materials, and mineral substrates.
21. A method for forming a hydrophobic barrier on a surface, comprising applying to said surface an effective amount of a composition, comprising:
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'') 0.25 to 99.99 wt.%, based on the total weight of (b'') and (b'''), of one or more transfer agents; and (b''') 0.01 to 99.75 wt.%, based on the total weight of (b'') and (b'''), of at least one active agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b'') 0.25 to 99.99 wt.%, based on the total weight of (b'') and (b'''), of one or more transfer agents; and (b''') 0.01 to 99.75 wt.%, based on the total weight of (b'') and (b'''), of at least one active agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
22. A method for cleaning and removing contaminants from a surface while forming a hydrophobic barrier on a surface, comprising applying to said surface an effective amount of a composition, comprising:
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b") 0.25 to 90.99 wt.%, based on the total weight of (b'') and (b'''), of one or more transfer agents; and (b''') 0.01 to 99.75 wt.%, based on the total weight of (b'') and (b'''), of at least one active agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
(a') 65 to 99.75 wt.%, based on the total weight of (a') and (b'), of one or more barrier materials; and (b') 0.25 to 35 wt.%, based on the total weight of (a') and (b'), of a mixture, said mixture comprising:
(b") 0.25 to 90.99 wt.%, based on the total weight of (b'') and (b'''), of one or more transfer agents; and (b''') 0.01 to 99.75 wt.%, based on the total weight of (b'') and (b'''), of at least one active agent, provided said transfer agent is present in said composition in an amount of at least 0.25 wt.%, based on the total weight of said composition.
23. The method of Claim 21 or 22, wherein said surface is selected from the group consisting of molds, ship hulls, leather, automobile surfaces, wood, metal, painted surfaces, floors, walls, billboards, train cars, paper, cardboard, pots, pans, cooking utensils, glass, china, plant foliage, polymers, plastics, fiberglass, fabrics, resins, composites including carbon fiber and graphitic materials, and mineral substrates.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11395098P | 1998-12-24 | 1998-12-24 | |
| US60/113,950 | 1998-12-24 | ||
| US11728399P | 1999-01-26 | 1999-01-26 | |
| US60/117,283 | 1999-01-26 | ||
| PCT/US1999/030003 WO2000038617A2 (en) | 1998-12-24 | 1999-12-23 | Compositions and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2356840A1 true CA2356840A1 (en) | 2000-07-06 |
Family
ID=26811670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002356840A Abandoned CA2356840A1 (en) | 1998-12-24 | 1999-12-23 | Compositions and methods of using the same |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1139981A4 (en) |
| AU (1) | AU2710300A (en) |
| CA (1) | CA2356840A1 (en) |
| WO (1) | WO2000038617A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008512373A (en) * | 2004-09-07 | 2008-04-24 | ダウ・コーニング・コーポレイション | Silicone adhesive containing antiperspirant |
| FR2876907B1 (en) * | 2004-10-27 | 2007-02-23 | Serge Bernstein | AQUEOUS SOLUTIONS FOR THE REDUCTION OF GREAT FABRICS |
| JP4965428B2 (en) * | 2005-02-28 | 2012-07-04 | マナック株式会社 | Free radical scavengers containing semicarbazide derivatives |
| AR062835A1 (en) * | 2007-08-29 | 2008-12-10 | Walter Montagni | A SELECTIVE STIMULATING COMPOSITION OF CICATRIZATION ITS PREPARATION AND APPLICATION |
| US11058793B2 (en) | 2011-05-16 | 2021-07-13 | Avery Dennison Corporation | Adhesive containing microparticles |
| BR112015019044B1 (en) | 2013-02-07 | 2022-02-08 | Avery Dennison Corporation | ANTIMICROBIAL ADHESIVE COMPOSITION, ITS MEDICAL ARTICLE, AND METHOD OF INCREASING THE RELEASE OF AN ANTIMICROBIAL AGENT FROM AN ADHESIVE COMPOSITION |
| WO2014151355A1 (en) | 2013-03-15 | 2014-09-25 | Avery Dennison Corporation | Transparent cover dressing application system and inclusion of label strip |
| EA201690565A1 (en) * | 2013-10-23 | 2016-10-31 | Юнилевер Н.В. | ANTI-PERSPIRENT COMPOSITION |
| US11337940B2 (en) | 2014-06-05 | 2022-05-24 | Avery Dennison Corporation | Articles with active agent concentrated at the substrate contacting surface and related methods |
| WO2016115639A1 (en) | 2015-01-23 | 2016-07-28 | Biocidium Biopharmaceuticals Inc. | Anti-bacterial compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3470292A (en) * | 1965-06-01 | 1969-09-30 | Colgate Palmolive Co | Film-forming composition containing a phosphatide and a siloxane |
| SU833240A1 (en) * | 1979-03-12 | 1981-05-30 | Московский Ордена Ленина И Орденатрудового Красного Знамени Химико- Технологический Институт Им.Д.И.Менделеева | Protective cream for hands |
| EP0408174A1 (en) * | 1989-07-12 | 1991-01-16 | Warner-Lambert Company | Antiseptic composition containing hexahydro-5-pyrimidinamine compounds |
| DE4341794C1 (en) * | 1993-12-08 | 1995-01-19 | Henkel Kgaa | Cosmetic and/or pharmaceutical compositions with improved skin feel |
| US5425938A (en) * | 1994-01-28 | 1995-06-20 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Polyamino salts of alpha-hydroxyacids, alpha-ketoacids and related compounds |
| US5665333A (en) * | 1995-01-17 | 1997-09-09 | Homola; Andrew M. | Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth |
| WO1997044007A2 (en) * | 1996-05-17 | 1997-11-27 | The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | A barrier cream comprising hexamethylenetetramine or derivative thereof |
| US5961958A (en) * | 1996-07-16 | 1999-10-05 | Four Star Partners | Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth |
| SE9604610D0 (en) * | 1996-12-16 | 1996-12-16 | Noviscens Ab | Medical composition |
-
1999
- 1999-12-23 CA CA002356840A patent/CA2356840A1/en not_active Abandoned
- 1999-12-23 EP EP99968903A patent/EP1139981A4/en not_active Withdrawn
- 1999-12-23 AU AU27103/00A patent/AU2710300A/en not_active Abandoned
- 1999-12-23 WO PCT/US1999/030003 patent/WO2000038617A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2710300A (en) | 2000-07-31 |
| WO2000038617A3 (en) | 2000-09-21 |
| EP1139981A2 (en) | 2001-10-10 |
| EP1139981A4 (en) | 2002-04-17 |
| WO2000038617A2 (en) | 2000-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6291031B2 (en) | Personal care composition containing pre-emulsified formulation | |
| US12364657B2 (en) | Method for coating keratin fibers | |
| AU737915B2 (en) | Method for making a product adhere to a surface | |
| DE60020051T2 (en) | Polar solvent-in-oil emulsions and multiple emulsions | |
| JP6873897B2 (en) | Hydrogel composition | |
| US6613755B2 (en) | Antimicrobial skin preparations containing organosilane quaternaries | |
| CN1131710C (en) | Skin care composition with improved skin hydration capability | |
| CA1129774A (en) | Anhydrous multi-purpose moisturizing composition | |
| ES2369853T3 (en) | COATED METAL PIRITIONA PARTICLES FOR THE TREATMENT OF MICROORGANISMS. | |
| WO1992000077A1 (en) | Improved ointment base and method of use | |
| TW200307560A (en) | Shampoo containing a cationic polymer and anti-dandruff particles | |
| JP2017530979A (en) | Method for improving mass feel and eyelash using a personal care composition containing a pre-emulsified formulation | |
| JP2010507671A (en) | Water-based skin care composition containing polyalkylsilsesquioxane powder emulsion and method for producing the same | |
| CA2356840A1 (en) | Compositions and methods of using the same | |
| JPS6127094B2 (en) | ||
| CN102655840A (en) | Personal care emulsions comprising waxy materials and organopolysiloxanes | |
| US6080416A (en) | Low tack lotion, gels and creams | |
| JPH09501668A (en) | Cleansing composition containing alkanoate as a conditioner | |
| JP6841654B2 (en) | Oil-in-water silicone emulsion composition | |
| WO2001070177A1 (en) | Silicone oil/cosolvent system concentrated in active liposoluble cosmetic substance(s), corresponding cosmetic emulsion and formulation | |
| KR20060096526A (en) | Shampoo composition for washing pets containing fragrance capsule | |
| Palanisamy et al. | Biosurfactants in Cosmetic Industry | |
| US9931287B2 (en) | Simple micro-particulate suspension of behentrimonium chloride with favorable distributive and adsorptive properties | |
| JP5988723B2 (en) | Hair treatment composition | |
| JP7475785B2 (en) | Oil-in-water emulsion composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |